{"text": "Abstract .Background .Systematic reviews and meta - analyses of pre - clinical studies , in vivo animal experiments in particular , can influence clinical care .Publication bias is one of the major threats of validity in systematic reviews and meta - analyses .Previous empirical studies suggested that systematic reviews and meta - analyses have become more prevalent until 2010 and found evidence for compromised methodological rigor with a trend towards improvement .We aim to comprehensively summarize and update the evidence base on systematic reviews and meta - analyses of animal studies , their methodological quality and assessment of publication bias in particular .", "label": "", "metadata": {}}
{"text": "The objectives of this systematic review are as follows : .To investigate the epidemiology of published systematic reviews of animal studies until present .To examine methodological features of systematic reviews and meta - analyses of animal studies with special attention to the assessment of publication bias .To investigate the influence of systematic reviews of animal studies on clinical research by examining citations of the systematic reviews by clinical studies .Eligible studies for this systematic review constitute systematic reviews and meta - analyses that summarize in vivo animal experiments with the purpose of reviewing animal evidence to inform human health .", "label": "", "metadata": {}}
{"text": "In addition to the inclusion of systematic reviews and meta - analyses identified by other empirical studies , we will systematically search Ovid Medline , Embase , ToxNet , and ScienceDirect from 2009 to January 2013 for further eligible studies without language restrictions .Two reviewers working independently will assess titles , abstracts , and full texts for eligibility and extract relevant data from included studies .Data reporting will involve a descriptive summary of meta - analyses and systematic reviews .Discussion .Results are expected to be publicly available later in 2013 and may form the basis for recommendations to improve the quality of systematic reviews and meta - analyses of animal studies and their use with respect to clinical care .", "label": "", "metadata": {}}
{"text": "Publication bias Animal experimentation Systematic review meta - analysis The OPEN Project .Electronic supplementary material .The online version of this article ( doi : 10 .1186/\u200b2046 - 4053 - 2 - 23 ) contains supplementary material , which is available to authorized users .Background .Pre - clinical research has its main purpose in enhancing our understanding of physiologic and pathologic processes .For instance , in the widely accepted Surviving Sepsis Guidelines recommendations regarding target arterial blood pressure for vasopressor use and positive end - expiratory pressure in the prevention of lung injury , draw on results from animal experiments [ 1 ] .", "label": "", "metadata": {}}
{"text": "SRs offer a structured and transparent way to comprehensively identify and evaluate the available evidence on a specific topic .Meta - analyses increase the precision and generalizability of effect estimates by quantitatively summarizing the results of individual studies included in an SR in order to provide a single best estimate with maximal statistical power [ 3 ] .SRs and meta - analyses of pre - clinical studies are still relatively rare in the medical literature .Mignini and Khan identified 30 SRs of laboratory animal experiments in 2006 , and Peters et al .found 86 using a more sensitive search strategy and a broader definition of laboratory animal experiments [ 4 , 5 ] .", "label": "", "metadata": {}}
{"text": "The validity and usefulness of the results of SRs and meta - analyses strongly depend on their methodological rigor .Assessing bias , such as publication bias , is essential , when conducting SRs .Different methods have been developed to graphically and statistically investigate publication bias [ 8 - 12 ] .Although all these methods have their limitations one should still try to address the likelihood of publication bias in each SR as thorough as possible [ 9 , 13 ] .While principles of critically appraising SRs of clinical research are well established , their application to SRs of pre - clinical studies appears variable [ 2 ] .", "label": "", "metadata": {}}
{"text": "Korevaar et al . reported that between 2005 and 2010 the proportion of meta - analyses of in vivo animal studies that assessed publication bias increased to 60 % ( 21/35 ) [ 6 ] .A recently published survey conducted in animal laboratories in the Netherlands reported that just about 50 % of animal experiments are published ; employees of for - profit organizations even estimated that only 10 % of animal experiments appear in peer - reviewed journals [ 14 ] .Lack of statistical significance was identified as one of several important reasons for non - publication .", "label": "", "metadata": {}}
{"text": "conducted their search for SRs of animal experiments in 2009/10 [ 6 ] .It remains unclear how the number and methodological quality , in particular assessment of publication bias , of such SRs evolved up to the present ( January 2013 ) , and to what extent they are cited by clinical studies .We will therefore conduct a comprehensive SR summarizing the results from Peters et al .and Korevaar et al .and updating the evidence base for SRs of animal experiments .Objectives .Methods .Eligibility criteria .To allow for a valid combination of results we will use similar criteria and search strategies to Peters et al .", "label": "", "metadata": {}}
{"text": "[ 5 , 6 ] , to identify relevant SRs and meta - analyses of animal experiments .In addition , we will use a second , more stringent , definition of an SR requiring besides a systematic search and explicit inclusion and exclusion criteria , also a focused research question and a systematic evaluation of the quality of the included studies [ 15 ] .For meta - analyses , a review has to report on some form of quantitative synthesis of results of more than one animal experiment .Articles including human studies in addition to animal studies will be considered too .", "label": "", "metadata": {}}
{"text": "we will exclude genome - wide association studies and animal experiments with the main purpose to learn more about fundamental biology , physical functioning or behavior and not to inform human healthcare .Search strategy .In addition , the bibliographies of any eligible articles identified will be checked for additional references .No language restrictions will be applied .The search strategy used by Korevaar et al .has been slightly modified with the support of a librarian / information specialist .The full search strategies are displayed in Additional file 1 .We will not search any grey literature ( that is , literature that has not been formally published ) .", "label": "", "metadata": {}}
{"text": "Two reviewers will independently and in duplicate screen titles and abstracts of search results .If a title and abstract can not be rejected with certainty by both reviewers , the full text of the paper will be retrieved and assessed for eligibility .Any disagreements among reviewers will be resolved by discussion and consensus or , if needed , third party arbitration .Data extraction .A specifically designed data extraction form will be developed and pilot - tested .Working in teams of two , we will independently extract relevant information from each eligible article .From all eligible SRs ( those included in Peters et al .", "label": "", "metadata": {}}
{"text": "Any disagreements will be resolved by discussion and consensus or , if needed , third party arbitration .We will use the ISI Web of Science Internet - based citation database to identify clinical publications citing included animal SRs .We will not do this for all included SRs but will rather focus on the following sample : SRs with meta - analysis published between 2005 and 2009 ( 29 articles ) and a random sample of 29 SRs without meta - analysis .Limiting to articles published until 2009 allows all articles to be available in the literature for at least 3 years until our analysis .", "label": "", "metadata": {}}
{"text": "Data reporting .Data reporting will involve a descriptive summary of meta - analyses and systematic reviews .We will report the study according to PRISMA guidelines [ 16 ] .Discussion .This SR aims to comprehensively summarize the epidemiology and methodological quality of SRs and meta - analyses of in vivo animal studies with special attention to the assessment of publication bias .SRs of animal studies can influence clinical care directly or indirectly through guidelines and clinical studies that are designed based on evidence from pre - clinical studies .In order to better understand the extent of that influence we plan to examine citations of identified reviews in publications of clinical studies .", "label": "", "metadata": {}}
{"text": "The strengths are that we will use a comprehensive approach to identify SRs and meta - analyses of in vivo animal studies through a sensitive search strategy and inclusion of previously identified articles .We will employ two definitions of SRs : a broader one that ensures comparability with previous empirical studies and a more stringent definition that will be applied to all articles meeting the broader criteria .A limitation of our protocol is that our results might be affected by publication bias because we will not search any grey literature .We are therefore limiting the generalizability of our results about methodological quality and publication bias to the published SRs of in vivo animal studies .", "label": "", "metadata": {}}
{"text": "Moreover , these reviews will serve as a foundation for a recommendations workshop , which will enable key members of the biomedical research community ( for example , funders , research ethics committees , journal editors , et cetera . ) to develop future policies and guidelines to reduce the frequency of non - publication and related biases .Abbreviations .Declarations .Acknowledgements .The OPEN Project is funded by the European Union Seventh Framework Programme ( FP7 - HEALTH.2011.4.1 - 2 ) under grant agreement n \u00b0 285453 .Electronic supplementary material .Competing interests .We declare that all authors and contributing members have no competing interests .", "label": "", "metadata": {}}
{"text": "MB , JM , and DB conceived of the study .MB , VG and EM designed the search strategies .MB drafted the manuscript with the help of KM , JM and DB .EvE , BL , EM , VG and GS critically reviewed the manuscript for important intellectual content .All authors read and approved the final version before submission .MB , JM and DB are guarantors .Authors ' Affiliations .Basel Institute for Clinical Epidemiology and Biostatistics , University Hospital Basel .Department for Clinical Epidemiology and Biostatistics , McMaster University .Center for Pediatric Clinical Studies , University Children 's Hospital Tuebingen .", "label": "", "metadata": {}}
{"text": "German Cochrane Centre , Institute of Medical Biometry and Medical Informatics , University Medical Center Freiburg .Cochrane Switzerland , IUMSP , University Hospital Lausanne .Institute of Medical Biometry and Medical Informatics , University Medical Center Freiburg .Clinical Research Centre \u00c8tienne Le Bel and Department of Medicine , University of Sherbrooke .References .Crit Care Med 2008 , 36 : 296 - 327 .PubMed View Article .Lamontagne F , Briel M , Duffett M , Fox - Robichaud A , Cook DJ , Guyatt G , Lesur O , Meade MO : Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis .", "label": "", "metadata": {}}
{"text": "PubMed View Article .Nordmann AJ , Kasenda B , Briel M : Meta - analyses : what they can and can not do .Swiss Medical Weekly 2012 , 142 : w13518 .PubMed .Mignini LEK , Khan KS : Methodological quality of systematic reviews of animal studies : a survey of reviews of basic research .BMC Med Res Method 2006 , 6 : 10 .View Article .Peters JL , Sutton AJ , Jones DR , Rushton L , Abrams KR : A systematic review of systematic reviews and meta - analyses of animal experiments with guidelines for reporting .", "label": "", "metadata": {}}
{"text": "PubMed .Korevaar DA , Hooft L , ter Riet G : Systematic reviews and meta - analyses of preclinical studies : publication bias in laboratory animal experiments .Lab Anim 2011 , 45 : 225 - 230 .PubMed View Article .Easterbrook PJ , Berlin JA , Gopalan R , Matthews DR : Publication bias in clinical research .Lancet 1991 , 337 : 867 - 872 .PubMed View Article .Bennett DA , Latham NK , Stretton C , Anderson CS : Capture - recapture is a potentially useful method for assessing publication bias .J Clin Epidemiol 2004 , 57 : 349 - 357 .", "label": "", "metadata": {}}
{"text": "Sterne JAC EM , Moher D : Chapter 10:Addressing reporting biases . 10.2.1Publication bias .In Cochrane Handbook of Systematic Reviews of Interventions .Version 5.1.0 Edited by : Higgins JPT , Green S. 2011 .[ [ updated March 2011].Duval S , Tweedie R : Trim and fill : A simple funnel - plot - based method of testing and adjusting for publication bias in meta - analysis .Biometrics 2000 , 56 : 455 - 463 .PubMed View Article .Moreno SG , Sutton AJ , Ades AE , Stanley TD , Abrams KR , Peters JL , Cooper NJ : Assessment of regression - based methods to adjust for publication bias through a comprehensive simulation study .", "label": "", "metadata": {}}
{"text": "PubMed View Article .Moreno SG , Sutton AJ , Thompson JR , Ades AE , Abrams KR , Cooper NJ : A generalized weighting regression - derived meta - analysis estimator robust to small - study effects and heterogeneity .Statistics in medicine .PubMed View Article .PLoS Medicine 2009 , 6 ( 7 ) : e1000100 .PubMed View Article .Ter Riet G , Korevaar DA , Leenaars M , Sterk PJ , Van Noorden CJF , Bouter LM , Lutter R , Elferink RPO , Hooft L : Publication Bias in Laboratory Animal Research : A Survey on Magnitude , Drivers , Consequences and Potential Solutions .", "label": "", "metadata": {}}
{"text": "PubMed View Article .Higgins JPT , Green S : Cochrane Handbook of Systematic Reviews of Interventions .Version 5.1.0 .[ [ updated March 2011].Moher D , Liberati A , Tetzlaff J , Altman DG , Group P : Preferred reporting items for systematic reviews and meta - analyses : the PRISMA statement .Ann Intern Med 2009 , 151 : 264 - 269 .W64 PubMed View Article .Copyright .\u00a9 Briel et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd.Data exploration , quality control and testing in single - cell qPCR - based gene expression experiments .", "label": "", "metadata": {}}
{"text": "Copyright \u00a9The Author 2012 .Published by Oxford University Press .All rights reserved .Abstract .Motivation : Cell populations are never truly homogeneous ; individual cells exist in biochemical states that define functional differences between them .New technology based on microfluidic arrays combined with multiplexed quantitative polymerase chain reactions now enables high - throughput single - cell gene expression measurement , allowing assessment of cellular heterogeneity .However , few analytic tools have been developed specifically for the statistical and analytical challenges of single - cell quantitative polymerase chain reactions data .Results : We present a statistical framework for the exploration , quality control and analysis of single - cell gene expression data from microfluidic arrays .", "label": "", "metadata": {}}
{"text": "We propose a statistical model accounting for the fact that genes at the single - cell level can be on ( and a continuous expression measure is recorded ) or dichotomously off ( and the recorded expression is zero ) .Based on this model , we derive a combined likelihood ratio test for differential expression that incorporates both the discrete and continuous components .Using an experiment that examines treatment - specific changes in expression , we show that this combined test is more powerful than either the continuous or dichotomous component in isolation , or a t -test on the zero - inflated data .", "label": "", "metadata": {}}
{"text": "The development of fluorescence - based flow cytometry ( FCM ) revolutionized single - cell analysis .Although populations of cells sorted by FCM using surface markers may appear monolithic , mRNA expression of specific genes within these cells can be heterogeneous ( Dalerba et al . , 2011 ) and could further discriminate cell subsets .On the other hand , classical gene expression experiments [ microarrays , RNA - seq , quantitative polymerase chain reactions ( qPCR ) ] richly characterize a cellular population but at the cost of reporting a summation of expression from many individual cells .", "label": "", "metadata": {}}
{"text": "This provides a technology that probes the stochastic nature of biochemical processes , resulting in relatively large cell - to - cell expression variability .This heterogeneity may carry important information ; thus , single - cell expression data should not be analysed in the same fashion as population - level data .At the scale of a single cell , biological variability ( the object of interest ) and technical variability ( a nuisance factor ) are often of the same magnitude , making it difficult to distinguish between the two .No expression ( i.e. the gene is off ) may be detected in individual cells owing to real biological effects , resulting in zero - inflation of otherwise continuous measures .", "label": "", "metadata": {}}
{"text": "Here , we focus on the reverse - transcriptase qPCR ( rt - qPCR)-based Fluidigm ( San Francisco , CA ) single - cell gene expression assay , which provides simultaneous measurements of up to 96 genes on mRNA sources as minute as a single cell .In traditional rt - qPCR , despite careful measurement of input cDNA concentrations , differences in starting material below the limit of detection require correction for reliable results ( Vandesompele et al . , 2002 ) .Subtraction of internal control genes , or averages thereof is typically used ( e.g. the -Ct method ) , and results are often reported in fold increase per cell ( Schmittgen and Livak , 2008 ) .", "label": "", "metadata": {}}
{"text": "Such normalization schemes are not directly applicable in single - cell gene expression experiments , nor is it obvious that they are needed .For single cells , the individual cell is the atomic unit of normalization and the amount of starting material naturally measured in number of cells per reaction .Even if one attempted direct application of traditional normalization approaches , the dichotomous nature of single - cell expression hinders their use .Nonetheless , it is important to test for and address any technical biases .We present a filtering approach for removing outlying measurements at the single - cell level that accounts for the dichotomous nature of the data .", "label": "", "metadata": {}}
{"text": "A typical goal of gene expression experiments is to search for differential expression across groups .The zero - inflation of expression in Fluidigm introduces problems for testing differential representation of cell subsets characterized by expression patterns , as well .Traditional tests of differential expression such as the t -test or other approaches based on normality are likely inappropriate for zero - inflated data ( Gottardo et al . , 2006 ; Smyth , 2004 ) .Approaches to this problem have varied .Powell et al .( 2012 ) used a winsorized z - transformation of the expression values and then treated them as continuous .", "label": "", "metadata": {}}
{"text": "( 2011 ) used the non - parametric , Kolmorgov - Smirnov test for differences in distribution to find differentially expressed genes after winsorizing .Flatz et al .( 2011 ) dichotomized the expression and worked with the binary trait .Of these authors , only Flatz et al .( 2011 ) and Glotzbach et al .( 2011 ) made use of formal tests of differential expression .However , as we will see later , both the continuous and discrete parts of the measurements are informative for differential expression and should be used .A parametric test allows directions of difference to be assessed .", "label": "", "metadata": {}}
{"text": "Using this model , we derive a likelihood ratio test ( LRT ) that can simultaneously test for changes in mean expression ( conditional on the gene being expressed ) and in the percentage of expressed cells .2 METHODS .2.1 Datasets and notations .We use three Fluidigm single - cell gene expression datasets described later in the text .We offer a brief overview of the assay technology used for our data .Desired cells ( e.g. antigen - specific CD8 + T cells ) are selected and lysed , and a cDNA library is generated through rt - qPCR .", "label": "", "metadata": {}}
{"text": "These products are loaded onto the Fluidigm chip , and gene - specific primers are added for single - cell gene expression quantitation .For the data presented here , we used a format plate , i.e. 96 genes across 96 cells .The design of the chip generates each combination of the 96 genes and 96 enriched cDNA libraries producing 9216 separate PCR reactions .After each cycle , the fluorescence is read .The cycle ( or interpolated fraction thereof ) at which the fluorescence crosses a pre - determined threshold is recorded , defined as the ' ct ' value .", "label": "", "metadata": {}}
{"text": "Data set A : Twenty - eight format plates of CMV- or HIV - specific CD8 + single cell T cells were isolated from 16 individuals .The donors ' cells were stimulated with one of four tetramers .Cells were sorted immediately after tetramer incubation ( ' unstimulated ' ) or after 3 hours of exposure ( ' stimulated ' ) .Approximately 90 individual cells were measured for each patient - stimulation combination ( ' unit ' ) .Data set C : Two subjects were considered .Approximately 40 cells were sorted per sub - population per subject across three arrays .", "label": "", "metadata": {}}
{"text": "100 cells per well on the array ) were isolated and assayed by Fluidigm technology .The expression measured in these 100-cell aggregates , after dividing by 100 , provides a ' biological ' average of expression per cell and can be compared with an in silico average of the single - cell measurements .The concordance between these two averages serves as a measure of experimental fidelity ( Lin , 1989 ) .Notations : The standard assumptions of qPCR - based assays apply to the Fluidigm technology , namely that the cycle threshold ( ct ) is inversely proportional to the log of fluorescence .", "label": "", "metadata": {}}
{"text": "The Fluidigm instrument returns the cycle threshold ( ct ) ; however , we find it more useful to work with the complement of ct , which we define as the expression threshold ( et ) .where is the maximum number of cycles used , 40 in our case .Assuming all reactions are in the exponential amplification phase , this quantity should be directly proportional to the log - abundance of mRNA , plus an intercept term corresponding to the number of cycles it takes for the minimally detectable quantity of mRNA to cross threshold .If the fluorescence does not cross the threshold after 40 cycles , then the Fluidigm instrument records a value of N / A , and we say that the gene is not detected .", "label": "", "metadata": {}}
{"text": "This assumption is supported by the idea that transcription of mRNA is thought to occur in bursts of activity ( Kaufmann and van Oudenaarden , 2007 ; Levsky et al . , 2002 ) , followed by quiescence .Other authors have noted this feature in single - cell expression studies as well ( Glotzbach et al . , 2011 ) .When looking at the concordance of the single - cell and 100-cell experiments , this assumption is reasonable and leads to better concordance than omitting the N / A values .As a consequence , we treat the undetected genes as unexpressed genes , and we set the corresponding et value to so that the mRNA abundance is zero ( i.e. ) .", "label": "", "metadata": {}}
{"text": "This results in a matrix of based expression values , , just as in array - based gene expression .Similarly , we will denote by the matrix of untransformed expression values , where .Usually , a well contains one cell , but the Fluidigm technology can be used with multiple cells per well to quantify the gene expression of a mixture of cells .As a consequence , we prefer to use the term ' well ' instead of ' cell ' .In the three datasets used here , wells will contain either 1 or 100 cells .", "label": "", "metadata": {}}
{"text": "As described previously , for a given cell , a gene can be defined as on ( i.e . a positive et value is recorded ) or as off ( i.e . the gene is undetected and ) .To simplify our model , we will denote by the indicator variable equal to one if the gene is expressed in well and zero otherwise .Following classical statistical conventions , we use upper cases to denote the random variables and lower cases to denote the values taken by these random variables .Using these notations , we introduce the following model of single - cell expression .", "label": "", "metadata": {}}
{"text": "S1 ) .Assuming a log - Normal model for is equivalent to modeling as normally distributed .The empirical distribution of the data ( Fig . 1 and Supplementary Figs S8-S10 ) motivates our selection of a log - normal distribution and follows observations of previous authors ( Bengtsson et al . , 2005 ) .Histogram and theoretical ( normal ) distribution of for single - cell ( left , light gray ) and 100-cell experiments ( right , dark gray ) .Genes FASLG , IFN- , BIRC3 and CD69 are depicted .", "label": "", "metadata": {}}
{"text": "Thus , in a particular gene , three parameters characterize the expression distribution : , the mean and standard deviation of the , and , the Bernoulli probability of expression . 2.3 Quality control and filtering .The Fluidigm assay is sensitive , and owing to the exponential amplification of starting mRNA , even minute contamination can render a measurement unreliable .Similarly , variation in cell preparation can have significant impact on the resulting experiment and data , such as unintentional empty wells , which would distort estimates of .This suggests identifying , and possibly removing outliers before conducting further analysis .", "label": "", "metadata": {}}
{"text": "We define the robust z - transformed positive expression value as .where the median and median absolute deviation ( MAD ) are calculated , for a given gene , over expressed cells ( i.e. ) , and is a scaling constant that gives the standard deviation in terms of the MAD for the normal distribution .Next , let be the Bernoulli variance - stabilizing transformation of the proportion of genes expressed in well .Then , we define the robust z - transformed fraction as .Step 1 removes wells where no cells were loaded , and thus all measured expression values are null .", "label": "", "metadata": {}}
{"text": "Finally , step 4 removes unreliable wells that either have an extreme proportion of expression or extreme cell gene expression values .The thresholds and control the tolerance to outliers ; therefore , typical advice for outlier thresholding applies .Biological replicates , such as the 100-cell replicates described in Section 2.1 , permit the assessment of intra - class deviance , and then the thresholds can be selected to minimize this deviance .We present such a calculation in the Supplementary Material .Using this approach , we find that picking works well for the datasets we consider here , see Section 3 . 2.4 Testing for ET differences between experimental groups .", "label": "", "metadata": {}}
{"text": "Here , we focus on testing differential gene expression between two paired - biological units , e.g. before and after stimulation .Our framework should be generalizable to other types of situations , see Section 4 .The classical test for changes in mean for samples with continuous measurements is the -test .Conversely , if only a change in were of interest , then a contingency table test ( Chi - square , Fisher 's exact or Bernoulli likelihood ratio ) is appropriate .However , in our case , we would like to test for a change in and simultaneously , as both could be biologically relevant .", "label": "", "metadata": {}}
{"text": "This can be accomplished using an LRT that would simultaneously test for differences in means or proportions of expression .Suppose that wells are assayed in each unit , though the unbalanced case ( ) would be treated similarly with obvious changes of notation .Based on ( 1 ) , the likelihood function for one gene across two biological units , omitting the gene index for clarity , is given by .The LRT statistic is then defined as the ratio of the null and alternative likelihoods obtained by replacing the unknown parameters with their null and alternative maximum likelihood estimates .", "label": "", "metadata": {}}
{"text": "An interesting observation is that the likelihood function given by ( 4 ) is the product of the Bernoulli likelihood for all cells and the log - normal likelihood for the expressed cells .It follows that the log - LRT statistic decomposes as a sum of a Bernoulli log - LRT test statistic and a log - normal log - LRT test statistic , as each component can be maximized independently .It thus combines the two sources of information in a natural way , and this decomposition allows post - hoc assessment of which of the component(s ) drive the detected difference by simply comparing the magnitude of the two log - LRTs .", "label": "", "metadata": {}}
{"text": "Applying classical asymptotic results about LRTs ( Wilks , 1938 ) , converges to a distribution with two degrees of freedom under .Some care is warranted in invoking this asymptotic result , as even for large , the sample size for the log - normal LRT will be .We show in Supplementary Figs S2 and S3 that the convergence is adequate for even under departures from normality .Below this value , it is possible to derive the null distribution of this statistic through permutation procedures as is commonly done for microarray data ( Ge et al . , 2003 ) .", "label": "", "metadata": {}}
{"text": "3 RESULTS .3.1 Distributional assumptions .In Figure 1 , we observe good agreement between the empirical distributions of positive et values and their postulated normal distribution for four genes in dataset A. This confirms that a log - normal model for the positive expression level , , is appropriate .Even cells in the lowest quantiles of et ( and lowest quantiles of expression ) still have expression far away from the bound at 0 , suggesting that undetected genes represent cells with null or negligible RNA abundance .It is also noteworthy that the difference between the means ( shown as a heavy , vertical line ) of the 100-cell replicates and single - cell replicates is approximately cycles , where is the expression frequency of gene in the single - cell experiments .", "label": "", "metadata": {}}
{"text": "As we will see the next section , inclusion of the unexpressed cells ( ) is important to accurately relate the expression level of the single - cell experiments to the 100-cell experiments .3.2 Concordance between 100-cell and single - cell experiments .The 100-cell aggregates ( see Section 2.1 ) allows us to assess the accuracy and reliability of our single - cell experiments by comparing this in vitro 100-cell expression to an in silico estimate obtained by averaging the expression of 100 single - cell measurements .The in silico average of signal in a gene and unit from 100 single - cell wells is where is the expression measurement of gene in cell and unit .", "label": "", "metadata": {}}
{"text": "In this case , we just use the expression of a gene unit and divide by the number of cells ( 100 ) .The concordance here is assessed both visually by plotting versus ( Fig . 2 ) and by calculating the concordance correlation coefficient ( ) between the two variables , which is often used to quantify reproducibility ( Lin , 1989 ) .The shifted log transformation allows visualization of both the discrete and continuous components while being on the et scale .Concordance between 100 cell and , the in silico average of single - cell wells for datasets A , B and C. In the top row , wells with are included and treated as exact zeroes .", "label": "", "metadata": {}}
{"text": "We first use this concordance experiment to test whether wells that do not cross the fluorescence threshold after should be treated as exact zeroes or missing values .If we suppose that implies an assay failure and the measurement should be discarded , we would simply compute the single - cell average over expressed cells , i.e. .Figure 2 demonstrates good concordance between the 100-cell and single - cell experiments when the undetected genes are treated as zeros .However , this is not the case when the zeros are treated as missing values . 3.3Filtering outlying cells .", "label": "", "metadata": {}}
{"text": "For a particular gene and unit , the decreases as we lower the filtering threshold and extreme values are filtered .Eventually , so many cells are removed that there is zero expression ( and a large deviance ) for the in silico estimate .Thus , we wish to find a set of values for the filtering parameters that would lead to the lowest measure across the three datasets used here .The addition of the scaling factor gives higher weight to combinations with more ex ante positive observations so that the contribution to the sum of squares would be smaller in gene unit combinations that have fewer expressed cells .", "label": "", "metadata": {}}
{"text": "Finally , the is computed on the scale to reduce the effect of extreme outliers .When 100-cell aggregates are available , one can optimize the filter parameters by minimizing the over possible combinations .In our case , we found that setting achieves the best reduction in across the three datasets explored here ( Supplementary Figs S4-S6 and Supplementary Table S1 ) .Using these values , our filtering criteria moderately improve the concordance between the single - cell and 100-cell experiments in two of the datasets but dramatically improve ( decrease ) the weighted sum of squares .", "label": "", "metadata": {}}
{"text": "3.4 Normalization and housekeeping genes .Other authors have noted that ' the gene transcript number is ideally standardized to the number of cells ' ( Vandesompele et al . , 2002 ) , which is the case with gene expression from sorted cells .Therefore , it is not entirely a surprise that we find little evidence for housekeeping genes providing useful normalization here .For a housekeeper to have good validity , it should have high cross - correlation with other housekeeping genes .This is not the case for housekeepers GAPDH and POLR2A , which in dataset A , in linear regression , have an .", "label": "", "metadata": {}}
{"text": "As the correlation between housekeepers is present primarily in cells we suspect suffered from technical error , we find little utility in normalization schemes .In fact , the use of housekeeping genes for normalization could even result in masking cellular artifacts that should be filtered .3.5 An efficient test of differential expression for single cells .This permits conducting a test for each gene in each subject for differences in and , as described in Section 2.4 .We plot the number of discoveries at various false discovery rates ( FDR ) in Figure 3 .The combined likelihood test produces the greatest number of discoveries over a wide range of FDR .", "label": "", "metadata": {}}
{"text": "Number of discoveries ( genes units ) versus FDR , by treatment , dataset A. The combined LRT is compared with a Bernoulli or normal - theory only LRT , as well as a t -test of the raw expression values ( scale ) , including zero measurements .Another feature of the combined LRT is its robustness to background gene frequency .Of course , if on average , then any test will be underpowered to detect group differences .But using only the continuous components amounts to \" throwing away \" data for genes with intermediate .And similarly , using only the dichotomous component results in a test insensitive to differences in in frequently expressed genes .", "label": "", "metadata": {}}
{"text": "The Bernoulli , normal - theory and combined LRTs are plotted .Asterisk indicates test is different from the combined test at 5 % significance in a Wilcoxon signed - rank test .A total of 65 genes were detected at an FDR of 1 % in at least one individual .We define as the negative P -value times an indicator variable , which is positive when stimulated groups have greater expression , and negative otherwise .Figure 5 plots a heatmap of signed P -values .The selected genes are in clustered rows ; the 16 individuals are arranged in columns by stimulation .", "label": "", "metadata": {}}
{"text": "From this , it is clear that genes cluster into upregulated and downregulated modules , and that there is much individual variability in response .Some genes appear to have stronger responses to particular antigens , such as the response to CMV ( red and purple columns ) in FASLG and CLEC2B. Heatmap of signed for selected genes ( rows , see main text ) and all 16 individuals ( columns ) .The color above each column indicates the antigen stimulation applied to the cells ; thus , individuals are randomly arranged in each antigen block .Red and purple ... .", "label": "", "metadata": {}}
{"text": "Current approaches for analysis of single - cell assays have incompletely used the salient features of the experiment , and the resulting inference can be suboptimal .In this article , we have presented a framework for data exploration , quality control and testing for differential expression using single - cell data .Our comparison of 100-cell and single - cell measurements shows that undetected genes in an assay should be treated as effective ' zeroes ' .Both the discrete , zero - inflated portion and continuous portion of single - cell expression data are meaningful for detecting outliers .", "label": "", "metadata": {}}
{"text": "Our LRT allows just that .Although we have suggested default parameters for the filtering of outliers , informed from several datasets , our defaults are likely conservative .They are 3 - 4 times larger than the most substantial difference in expression between experimental groups we observed .Acquiring forms of ground - truth besides ' bulk ' experiments ( in our case , 100-cell aggregates ) could allow forming tighter bounds .As in any outlier - based filtering procedure , it is desirable to tune for the problem at hand .The thresholds and should be different when eliminating potential technical error is of greatest concern than when one is most interested in searching for biological heterogeneity .", "label": "", "metadata": {}}
{"text": "This approximation is relatively accurate and robust to the distributional form of when the expected number of expressed cells is greater than 8 ( see Supplementary Material ) .Otherwise , approximating the null distribution using permutations as in Ge et al . , 2003 is more appropriate .Further work , incorporating a mixed - effects model to our LRT , could extend its applicability .The test outlined in this article may not be appropriate in cases where traits of interest are not blocked within individuals ( e.g .In this case , one wishes to identify gene expression changes across groups , despite high individual - to - individual heterogeneity .", "label": "", "metadata": {}}
{"text": "Single - cell gene expressions assays have already been shown to be useful in multiple studies and will become even more routine once sequencing at the single - cell level becomes practical ( Ramskold et al ., 2012 ; Varadarajan et al . , 2011 ) .As a consequence , the development of effective statistical methods to analyse such data is becoming increasingly important .This article offers a coherent framework for researchers using this nascent technology .Funding : Intramural Research Program of the National Institute of Allergy and Infectious Diseases , National Institute of Health and the Collaboration for AIDS Vaccine Discovery [ # 38650 ] ; National Institute of Health [ U19 AI089986 - 01 , R01 EB008400 to R .", "label": "", "metadata": {}}
{"text": "Supplementary Material .REFERENCES .Bengtsson M , et al .Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mRNA levels .Genome Res .[PubMed ] .Dalerba P , et al .Single - cell dissection of transcriptional heterogeneity in human colon tumors .Nat .Biotechnol .[ PMC free article ] [ PubMed ] .Flatz L , et al .Single - cell gene - expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene - based vaccines .Proc .Natl Acad .", "label": "", "metadata": {}}
{"text": "USA .[PubMed ] .Ge Y , et al .Resampling - based multiple testing for microarray data analysis .TEST .Glotzbach JP , et al .An information theoretic , microfluidic - based single cell analysis permits identification of subpopulations among putatively homogeneous stem cells .PLoS One .2011 ; 6 : e21211 .[ PMC free article ] [ PubMed ] .Gottardo R , et al .Bayesian robust inference for differential gene expression in microarrays with multiple samples .Biometrics .[PubMed ] .Higuchi R , et al .Simultaneous amplification and detection of specific DNA sequences .", "label": "", "metadata": {}}
{"text": "[PubMed ] .Kalisky T , Quake SR .Single - cell genomics .Nat .Meth .[PubMed ] .Karlen Y , et al .Statistical significance of quantitative PCR .BMC Bioinformatics .[ PMC free article ] [ PubMed ] .Kaufmann BB , van Oudenaarden A. Stochastic gene expression : from single molecules to the proteome .Curr .Opin .Genet .Dev .[PubMed ] .Levsky JM , et al .Single - cell gene expression profiling .Science .[PubMed ] .Lin LI .A concordance correlation coefficient to evaluate reproducibility .", "label": "", "metadata": {}}
{"text": "[PubMed ] .Powell AA , et al .Single cell profiling of circulating tumor cells : transcriptional heterogeneity and diversity from breast cancer cell lines .PLoS One .2012 ; 7 : e33788 .[ PMC free article ] [ PubMed ] .Ramskold D , et al .Full - length mRNA - Seq from single - cell levels of RNA and individual circulating tumor cells .Nat .Biotech .[ PMC free article ] [ PubMed ] .Schmittgen TD , Livak KJ .Analyzing real - time PCR data by the comparative CT method .", "label": "", "metadata": {}}
{"text": "Protocols .[PubMed ] .Smyth GK .Linear models and empirical bayes methods for assessing differential expression in microarray experiments .Stat .Appl .Genet .Mol .Biol .2004 ; 3 article 3 .[PubMed ] .Vandesompele J , et al .Accurate normalization of real - time quantitative RT - PCR data by geometric averaging of multiple internal control genes .Genome Biol .2002 ; 3 RESEARCH0034 .[ PMC free article ] [ PubMed ] .Varadarajan N , et al .A high - throughput single - cell analysis of human CD8 T cell functions reveals discordance for cytokine secretion and cytolysis .", "label": "", "metadata": {}}
{"text": "Invest .[ PMC free article ] [ PubMed ] .Wilks SS .The large - sample distribution of the likelihood ratio for testing composite hypotheses .Ann .Math .Stat .Adverse drug events ( ADEs ) , defined as adverse patient outcomes caused by medications , are common and difficult to detect .Electronic detection of ADEs is a promising method to identify ADEs .We performed this systematic review to characterize established electronic detection systems and their accuracy .We identified studies evaluating electronic ADE detection from the MEDLINE and EMBASE databases .We included studies if they contained original data and involved detection of electronic triggers using information systems .", "label": "", "metadata": {}}
{"text": "Forty - eight studies met our inclusion criteria .Twenty - four ( 50 % ) studies reported rule accuracy but only 9 ( 18.8 % ) utilized a proper gold standard ( chart review in all patients ) .Rule accuracy was variable and often poor ( range of sensitivity : 40%-94 % ; specificity : 1.4%-89.8 % ; positive predictive value : 0.9%-64 % ) .5 ( 10.4 % ) studies derived or used detection rules that were defined by clinical need or the underlying ADE prevalence .Detection rules in 8 ( 16.7 % ) studies detected specific types of ADEs .", "label": "", "metadata": {}}
{"text": "Few ADE detection algorithms considered clinical priorities .To enhance the utility of electronic detection systems , there is a need to systematically address these factors .Full - text .Electronic detection of ADEs is a promising method to identify ADEs .We performed this systematic review to characterize established electronic detection systems and their accuracy .Methods We identified studies evaluating electronic ADE detection from the MEDLINE and EMBASE databases .We included studies if they contained original data and involved detection of electronic triggers using information systems .We abstracted data regarding rule characteristics including type , accuracy , and rationale .", "label": "", "metadata": {}}
{"text": "Twenty - four ( 50 % ) studies reported rule accuracy but only 9 ( 18.8 % ) utilized a proper gold standard ( chart review in all patients ) .Rule accuracy was variable and often poor ( range of sensitivity : 40%e94 % ; specificity : 1.4%e89.8 % ; positive predictive value : 0.9%e64 % ) .5 ( 10.4 % ) studies derived or used detection rules that were defined by clinical need or the underlying ADE prevalence .Detection rules in 8 ( 16.7 % ) studies detected specific types of ADEs .Conclusion Several factors led to inaccurate ADE detection algorithms , including immature underlying information systems , non - standard event definitions , and variable methods for detection rule validation .", "label": "", "metadata": {}}
{"text": "To enhance the utility of electronic detection systems , there is a need to systematically address these factors .INTRODUCTION Adverse drug events ( ADEs ) occur when patients experience medication related harm .ADEs occur in 6.5 % of hospitalized patients and are considered a major threat to patient safety.1To reduce ADEs it is necessary to systematically detect them . Unfor- tunately , voluntary incident reporting , retrospective chart reviews , and prospective ADE surveillance , representing the currently used methods of ADE detection , are limited in effectiveness or afford- ability . 'Electronic ADE detection ' uses computer- based algorithms to automatically screen electronic healthcare databases for events suggestive of ADEs .", "label": "", "metadata": {}}
{"text": "There are several advantages of using electronic methods for ADE detection .They are based on routinely collected , readily available data and are therefore less expensive and less time - consuming pharmacy , and than medical record review .The accuracy of electronic ADE detection is a function of the availability of integrated data systems and their criteria.8ADE detection rules based on non - inte- grated information systems will be less specific because they will be restricted to single clinical criteria .Finally , electronic ADE detection is further complicated by inconsistent ADE definitions,4 nomenclature,3and methods for defining a gold standard.7 9These inconsistencies make building reliable ADE detection systems difficult , and are problematic for internal and external validity .", "label": "", "metadata": {}}
{"text": "Our primary outcome was to determine the published detection rules .Secondary outcomes were to determine ( 1 ) if studies derived detection rules based on prior knowledge of ADE prevalence , and ( 2 ) if the rules used by studies detected specific ADE types or generic events .The results of this review are useful to teams implementing electronic ADEs or interpreting the results from an electronic ADE detection system .eliminatereviewer accuracy of METHODS Data sources We obtained relevant citations from the MEDLINE ( 1948e2011 ) and EMBASE ( 1980e2011 ) databases using the search strategy outlined in online supplementary appendix 1 ( search date : January 21 , 2011 ) .", "label": "", "metadata": {}}
{"text": "We also manually searched the references of included studies for additional articles not identified in the database search .Study selection We retrieved full text articles if the title or abstract suggested that investigators evaluated a computer- based system of ADE or ADR detection . toc ) .doi:10.1136/amiajnl-2011 - 00045431Review .Page 2 . the following information systems : laboratory , pharmacy , radi- ology , or administrative .Data abstraction Two of three reviewers ( AJ , CC , or CL ) independently abstracted the data .Discrepancies were resolved by discussion involving a third reviewer ( AF ) if necessary to achieve consensus .", "label": "", "metadata": {}}
{"text": "We abstracted data on rule characteristics including the information system(s ) used as well as rule type and criteria .Rule criteria referred to the specific data elements employed by the rules to detect the ADEs ( eg , ICD code or antidote drugs ) .We also abstracted the actual detection rules / outcome triggers employed by each study .Finally , we determined if the detection rules were used to detect specific ADEs ( eg , bleeding as a result of anticoagulation ) or generic ADEs ( eg , an injury resulting from an intervention related to a drug ) .", "label": "", "metadata": {}}
{"text": "To determine the proportion of studies that properly assessed rule accuracy , we abstracted data about the gold standard used .We categorized studies that used a gold standard into three groups : ones that applied chart review on every study patient , studies that applied chart review on only electronic screen - positive patients , and those that used some other gold standard .We abstracted infor- mation regarding the methods used in studies that presented a measure of accuracy but did not employ a true gold standard .We also abstracted data on the overall and individual rule accuracy reported by the studies .", "label": "", "metadata": {}}
{"text": "We generally defined studies to have considered the underlying ADE prevalence ( or to have based their choice on clinical need ) if their detection focused on the most frequent ADEs or those that cause the greatest harm .RESULTS The search in MEDLINE and EMBASE identified 2045 citations , of which 85 articles were retrieved and reviewed in full .We excluded 52 articles for the various reasons outlined in figure 1 .We further identified 17 additional articles from manually searching the references of included articles .Our final analysis included 48 cohort studies ( 50 articles ) .", "label": "", "metadata": {}}
{"text": "ADE , adverse drug event .Study selection .This figure 32J Am Med Inform Assoc 2012;19:31e38 .doi:10.1136/amiajnl-2011 - 000454 Review .Page 3 . that referenced the same study as another included article , we abstracted data from all references .Study characteristics The studies were published between 1988 and 2009 , the majority of them in recent years .The median sample size was 3889 observations ( 25th to 75th percentile range , 430e38467 ) .Forty - one ( 85.4 % ) studies were conducted on hospitalized patients , three ( 6.3 % ) on outpatients and four ( 8.3 % ) on both .", "label": "", "metadata": {}}
{"text": "The detection rules in 28 ( 58.3 % ) studies were based on a single criterion and the rules in the other 19 ( 39.6 % ) studies used combined criteria from multiple informa- tion systems .One study used rules with a single criterion as well as rules with multiple criteria.34The rule criteria in the majority of studies using multiple databases was combinations of drug , serum drug , and laboratory data to detect ADEs .Only eight ( 16.7 % ) studies used detection rules to detect specific ADE types .Three ( 6.3 % ) studies30 33 58targeted specific drugs that caused ADEs , while four ( 8.3 % ) studies14 43 44 51 targeted certain conditions .", "label": "", "metadata": {}}
{"text": "Studies that did not detect specific types used rules designed to capture the presence of any ADE .Twenty studies ( 41 % ) evaluated rules which were used retrospectively to identify ADEs , while 28 studies ( 58 % ) evaluated rules which were used to alert physicians to the presence of an ADE .Studies that assessed the accuracy of detection rules Half of the studies ( 50 % ) reported some measure of accuracy .Fourteen ( 29.2 % ) of these studies used a ' gold standard , ' while the remaining 10 ( 20.8 % ) studies calculated accuracy using the results of ADE verification .", "label": "", "metadata": {}}
{"text": "Since the absolute number of ADEs was unknown , these studies could only calculate the positive predictive value as a measure of rule accuracy ( table 3 ) .Of the gold standard studies , nine ( 18.8 % ) used chart review in every study patient independent of the results of electronic detection .Two ( 4.2 % ) studies used chart review in the rule positive patients only , so , as in the studies using verification , only PPV could be calculated .However , one of these studies also reported sensitivity and specificity by using estimates of visits with or without ADEs.11 31 Three ( 6.3 % ) studies used methods other than chart review alone .", "label": "", "metadata": {}}
{"text": "Ranges for sensitivity , specificity , and positive predictive value were 40%e94 % , 1.4%e 89 % , and 0.9%e64 % , respectively .Only two studies presented negative predictive values .The list of individual rules and indi- vidual rule accuracy , where available , are found in online supplementary appendix 2 .Reason for chosen ADE detection rules It was unclear in four ( 8.3 % ) studies12 16 45 54why they selected the rules they employed to detect ADEs .Twelve ( 31.3 % ) studies5 10 13 17e20 23 24 26 28 36 55chose their rules based on the clinical information available in their information system(s ) , Table 1 Study characteristics Study characteristicN[48 studies Median sample size ( 25th ?", "label": "", "metadata": {}}
{"text": "ADE , adverse drug event .J Am Med Inform Assoc 2012;19:31e38 .doi:10.1136/amiajnl-2011 - 000454 33 Review .Page 4 .doi:10.1136/amiajnl-2011 - 000454 Review .Page 5 . 16 ( 33.3 % ) studies11 21 22 25 27 31 32 37e39 41 42 47e50 52used previous available rules and four ( 8.3 % ) studies4 15 34 35used a combination of these reasons .Three ( 6.3 % ) studies43 51 57based their decision on a specific research question or condition of interest and five ( 10.4 % ) studies29 37 40 53 56on previous research or common practice ( eg , use of known antidotes for ADRs ) .", "label": "", "metadata": {}}
{"text": "Currently , there is no systematic approach to validating ADE detection methods .An appropriate comparative gold standard is not routinely used , and if used , differs across studies resulting in varying measures of accuracy .Of the 24 studies in our system- atic review that assessed rule accuracy , slightly less than half had appropriately used a gold standard and were thus able to measure rule sensitivity and specificity .The accuracy reported from these few studies was generally low but displayed a wide range , making it difficult to draw conclusions about the overall effectiveness of electronic ADE detection .", "label": "", "metadata": {}}
{"text": "It can be challenging to obtain research funds to perform this work .As a result , most institutions will implement these rules with only partial evaluations , at best .A , alert ; ADE , adverse drug event ; ADR , adverse drug reaction ; C , combined centers ; D , detection ; ICU , intensive care unit ; M , multicenter ; NR , not recorded ; S , single center .J Am Med Inform Assoc 2012;19:31e38 .doi:10.1136/amiajnl-2011 - 00045435Review .Page 6 . detection methods.7 9The included studies varied considerably in the information system(s ) used and the rule criterion .", "label": "", "metadata": {}}
{"text": "Single information systems restrict the number of criteria that can be used in electronic detection rules , which can reduce rule accuracy .yChart review was conducted in all patients at one of the study sites only .zChart review was part of a surveillance program .ADR , adverse drug reaction ; NPV , negative predictive value ; PPV , positive predictive value .36 J Am Med Inform Assoc 2012;19:31e38 .doi:10.1136/amiajnl-2011 - 000454 Review .Page 7 . potassium less than 3.0 mmol / l or more than 6 mmol / l'13or ' patient receiving diphenhydramine'35have high false positive rates because their occurrence is most commonly not related to an ADE .", "label": "", "metadata": {}}
{"text": "Whether the respiratory compromise is due to an excess post - operative intravenous rate or diastolic dysfunction , the patient will still likely undergo testing with a chest x - ray , cardiac enzymes , and an electrocardiogram and be treated with oxygen , diuretics , and morphine .Since most current electronic records do not record diagnoses but do capture tests and treatments , the two cases would look the same to an electronic ADE detection system even though in one case it is an ADE and the other it is not .The same issue can lead to insensitive rules as well .", "label": "", "metadata": {}}
{"text": "In these cases , the adverse event will require documentation of an ADE - related diagnosis in the electronic record .Since these are sometimes not stored electronically , detection of such ADEs will be impossible .We also examined how studies derived or utilized detection rules .Very few studies ( 10 % ) derived or used rules that were defined either by clinical need or the underlying ADE prevalence .A number of studies used or developed rules for particular ADEs only because they were possible or the required source data systems were available .These studies did not necessarily detect the ADEs that they should be detecting and can not help us identify what the most prevalent and important ADEs are .", "label": "", "metadata": {}}
{"text": "Attempting to identify all ADEs is an extremely complex task and greater success may be achieved by focusing on key ADEs .In addition to the issues with the current literature described above , it was noted that there are few studies from hospitals outside of the USA .Thirty - one ( 65 % ) of the 48 studies in our systematic review were American .There is a need to study elec- tronic triggers using patients in other countries , including Canada , for two reasons .First , other countries have different healthcare systems ( eg , Canada has universal healthcare ) , so hospital utili- zation patterns and in - hospital medication use may be different .", "label": "", "metadata": {}}
{"text": "In addition , structural differences exist in information systems .For example , discharge abstracts in Canada are currently based on ICD-10 , whereas in the USA they are based on ICD-9 .Further- more , hospital discharge abstracts from Canadian hospitals indi- cate whether or not recorded diagnoses are hospital complications .These differences in coding diagnoses affect the type of rule criteria that can be used in each country to detect ADEs .This review characterized existing reports on the use of elec- tronic detection of ADEs and assessed their accuracy .The main limitations of this study are that it is purely descriptive and the studies are very heterogeneous .", "label": "", "metadata": {}}
{"text": "Nonetheless , our review did highlight some impor- tant methodological limitations in the existing published studies of electronic ADE detection .We identified three main limitations : ( 1 ) most studies did not properly assess rule accuracy ; ( 2 ) extremely few studies considered the underlying ADE prevalence whenchoosingwhichrulestoderiveoruse;and(3)themajorityof rules did not detect specific ADE types .These limitations need to be addressed to realize the full potential of electronic detection of ADEs .Future research should also focus on the identification of rule characteristics which predict benefit .It is notable that we are unable to make recommendations on which information systems are most likely to be beneficial in the development of electronic alerts .", "label": "", "metadata": {}}
{"text": "In the development of new alerts , investigators and system developers should pay more attention to the relative prevalence of specific ADEs and focus on those which are most common and serious .We suggest a more rigorous approach to rule development and reporting .As a basis for future advances , there is a need for the industry to develop and adopt universal standards in ADE classification .There is existing work in this area , however , international consensus would be helpful .Even in the absence of this there are some general guidelines which should be followed for future publications reporting on the accuracy of electronic ADE rules .", "label": "", "metadata": {}}
{"text": "Third , the report needs to link the clinical concepts defined by the ADE to data definitions .Fourth , investigators need to adhere to appropriate epidemio- logical techniques for reporting rule test characteristics .Adher- ence to these guidelines will facilitate progress in this field as they will improve the generalizability and reproducibility of the published work .Competing interests None .Provenance and peer review Not commissioned ; externally peer reviewed .REFERENCES 1 .Bates DW , Cullen DJ , Laird N , et al .Incidence of adverse drug events and potential adverse drug events .", "label": "", "metadata": {}}
{"text": "ADE Prevention Study Group .JAMA 1995;274:29e34 .Bates DW , Evans RS , Murff H , et al .Detecting adverse events using information technology .J Am Med Inform Assoc 2003;10:115e28 .Thurmann PA , Thurmann PA .Methods and systems to detect adverse drug reactions in hospitals .Drug Saf 2001;24:961e8 .Table 4 Studies with detection rules defined by clinical need Study ADE / ADR prevalence considered Nebeker et al , 200744 Two of the most common ADE types , delirium / psychosis and bleeding / anticoagulation problems , for which there were administrative data , were selected for detection .", "label": "", "metadata": {}}
{"text": "Increased reports of spironolactone - related life - threatening hyperkalemia motivated the implementation of a detection rule for this ADE type .Detection rules for drug - induced liver injury were selected because liver damage was considered the most frequent type of ADR leading to drug withdrawal from the market .Detection rules targeted 37 drug- or drug class - specific ADEs that represent the most common ADE categories described in the Harvard Medical Practice Study .Hartis et al , 200530 Huang et al , 200533 Bagheri et al , 200014 Raschke et al , 199846 ADE , adverse drug event ; ADR , adverse drug reaction .", "label": "", "metadata": {}}
{"text": "doi:10.1136/amiajnl-2011 - 00045437Review .Page 8 .Jha AK , Kuperman GJ , Teich JM , et al .Identifying adverse drug events : development of a computer - based monitor and comparison with chart review and stimulated voluntary report .J Am Med Inform Assoc 1998;5:305e14 .Classen DC , Pestotnik SL , Evans RS , et al .Computerized surveillance of adverse drug events in hospital patients .JAMA 1991;266:2847e51 .Gandhi TK , Seger DL , Bates DW .Identifying drug safety issues : from research to practice .Int J Qual Health Care 2000;12:69e76 .", "label": "", "metadata": {}}
{"text": "Linking laboratory and pharmacy : opportunities for reducing errors and improving care .Arch Intern Med 2003;163:893e900 .Kilbridge PM , Classen DC .Automated surveillance for adverse events in hospitalized patients : back to the future .Qual Saf Health Care 2006;15:148e9 .Handler SM , Altman RL , Perera S , et al .A systematic review of the performance characteristics of clinical event monitor signals used to detect adverse drug events in the hospital setting .J Am Med Inform Assoc 2007;14:451e8 .Gurwitz JH , Field TS , Harrold LR , et al .Incidence and preventability of adverse drug events among older persons in the ambulatory setting .", "label": "", "metadata": {}}
{"text": "Honigman B , Lee J , Rothschild J , et al .Using computerized data to identify adverse drug events in outpatients .J Am Med Inform Assoc 2001;8:254e66 .Al Malaq HM , Al Aqeel SA , Al Sultan MS .Adverse drug reactions related hospitalization identified by discharge ICD-9 codes in a university hospital in Riyadh .Saudi Med J 2008;29:1145e50 .Azaz - Livshits T , Levy M , Sadan B , et al .Computerized survelliance of adverse drug reactions in hospital : pilot study .Br J Clin Pharmacol 1998;45:309e14 .Bagheri H , Michel F , Lapeyre - Mestre M , et al .", "label": "", "metadata": {}}
{"text": "Br J Clin Pharmacol 2000;50:479e84 .Brown S , Black K , Mrochek S , et al .RADARx : recognizing , assessing , and documenting adverse Rx events .Proc AMIA Symp 2000;101e5 .Brvar MF , Fokker N , Bunc M , et al .The frequency of adverse drug reaction related admissions according to method of detection , admission urgency and medical department specialty .BMC Clin Pharmacol 2009;9:8 .Burgess CL , Holman CD , Satti AG .Adverse drug reactions in older Australians , 1981 - 2002 .Med J Aust 2005;182:267e70 .Carroll R , McLean J , Walsh M. Reporting hospital adverse events using the Alfred Hospital 's morbidity data .", "label": "", "metadata": {}}
{"text": "Classen DC , Pestotnik SL , Evans RS , et al .Description of a computerized adverse drug event monitor using a hospital information system .Hosp Pharm 1992;27:774 , 776e9 , 783 .Classen DCM , Pestotnik SLM , Evans RSP , et al .Adverse drug events in hospitalized patients : excess length of stay , extra costs , and attributable mortality .JAMA 1997;277:301e6 .Dalton - Bunnow MF , Halvachs FJ .Computer - assisted use of tracer antidote drugs to increase detection of adverse drug reactions : a retrospective and concurrent trial .Hosp Pharm 1993;28:746e9 , 752e5 .", "label": "", "metadata": {}}
{"text": "Incidence and costs of adverse drug reactions during hospitalisation : computerised monitoring versus stimulated spontaneous reporting .Drug Saf 2000;22:161e8 .Dormann H , Crigee - Rieck M , Neubert A , et al .Implementation of a computer- assisted monitoring system for the detection of adverse drug reactions in gastroenterology .Alimen Pharmacol Ther 2004;19:303e9 .Egger T , Dormann H , Ahne G , et al .Identification of adverse drug reactions in geriatric inpatients using a computerised drug database .Drugs Aging 2003;20:769e76 .Einbinder JS , Scully K. Using a clinical data repository to estimate the frequency and costs of adverse drug events .", "label": "", "metadata": {}}
{"text": "2001:154e8 .Evans RS , Pestotnik SL , Classen DC , et al .Development of a computerized adverse drug event monitor .Proc Annu Symp Comput Appl Med Care 1991:23e7 .Evans RS , Pestotnik SL , Classen DC , et al .Preventing adverse drug events in hospitalized patients .Ann Pharmacother 1994;28:523e7 .Field TS , Gurwitz JH , Harrold LR , et al .Strategies for detecting adverse drug events among older persons in the ambulatory setting .J Am Med Inform Assoc 2004;11:492e8 .Gronroos P , Irjala K , Heiskanen J , et al .", "label": "", "metadata": {}}
{"text": "Scand J Clin Lab Invest Suppl 1995;222:31e6 .Hartis CE , Gum MO , Lederer JW Jr. Use of specific indicators to detect warfarin- related adverse events .Am J Health Syst Pharm 2005;62:1683e8 .Honigman B , Light P , Pulling RM , et al .A computerized method for identifying incidents associated with adverse drug events in outpatients .Int J Med Inform 2001;61:21e32 .Hope C , Overhage JM , Seger A , et al .A tiered approach is more cost effective than traditional pharmacist - based review for classifying computer - detected signals as adverse drug events .", "label": "", "metadata": {}}
{"text": "Huang C , Noirot LA , Reichley RM , et al .Automatic detection of spironolactonedrelated adverse drug events .AMIA Annu Symp Proc 2005:989 .Hwang SH , Lee S , Koo HK , et al .Evaluation of a computer - based adverse - drug- event monitor .Am J Health Syst Pharm 2008;65:2265e72 .Jha AK , Kuperman GJ , Rittenberg E , et al .Identifying hospital admissions due to adverse drug events using a computer - based monitor .Pharmacoepidemiol Drug Saf 2001;10:113e19 .Jha AK , Laguette J , Seger A , et al .", "label": "", "metadata": {}}
{"text": "A prospective evaluation of a commercial application .J Am Med Inform Assoc 2008;15:647e53 .Johnstone DM , Kirking DM , Vinson BE .Comparison of adverse drug reactions detected by pharmacy and medical records departments .Am J Health Syst Pharm 1995;52:297e301 .Kilbridge PM , Alexander L , Ahmad A. Implementation of a system for computerized adverse drug event surveillance and intervention at an academic medical center .J Clin Outcomes Manage 2006;13:94e100 .Kilbridge PM , Campbell UC , Cozart H , et al .Automated surveillance for adverse drug events at a community hospital and an academic medical center .", "label": "", "metadata": {}}
{"text": "Koch KE .Use of standardized screening procedures to identify adverse drug reactions .Am J Hosp Pharm 1990;47:1314e20 .Kuperman GJ , Teich JM , Bates DW , et al .Representing hospital events as complex conditionals .Proc Annu Symp Comput Appl Med Care 1995:137e41 .Levy M , Azaz - Livshits T , Sadan B , et al .Computerized surveillance of adverse drug reactions in hospital : implementation .Eur J Clin Pharmacol 1999;54:887e92 .Movig KL , Leufkens HG , Lenderink AW , et al .Association between antidepressant drug use and hyponatraemia : a case - control study .", "label": "", "metadata": {}}
{"text": "Nebeker JR , Yarnold PR , Soltysik RC , et al .Developing indicators of inpatient adverse drug events through nonlinear analysis using administrative data .Med Care 2007;45:S81e8 .Payne TH , Savarino J , Marshall R , et al .Use of a clinical event monitor to prevent and detect medication errors .Proc AMIA Symp 2000:640e4 .Raschke RA , Gollihare B , Wunderlich TA , et al .A computer alert system to prevent injury from adverse drug events : development and evaluation in a community teaching hospital .JAMA 1998;280:1317e20 .Seger AC , Jha AK , Bates DW .", "label": "", "metadata": {}}
{"text": "Drug Saf 2007;30:817e24 .Senst BL , Achusim LE , Genest RP , et al .Practical approach to determining costs and frequency of adverse drug events in a health care network .Am J Health Syst Pharm 2001;58:1126e32 .Silverman JB , Stapinski CD , Huber C , et al .Computer - based system for preventing adverse drug events .Am J Health Syst Pharm 2004;61:1599e603 .Szekendi MK , Sullivan C , Bobb A , et al .Active surveillance using electronic triggers to detect adverse events in hospitalized patients .Qual Saf Health Care 2006;15:184e90 .", "label": "", "metadata": {}}
{"text": "Detection and incidence of drug - induced agranulocytosis in hospital : a prospective analysis from laboratory signals .Eur J Clin Pharmacol 2007;63:221e8 .Tegeder I , Levy M , Muth - Selbach U , et al .Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals .Br J Clin Pharmacol 1999;47:557e64 .Thuermann PA , Windecker R , Steffen J , et al .Detection of adverse drug reactions in a neurological department : comparison between intensified surveillance and a computer - assisted approach .Drug Saf 2002;25:713e24 .", "label": "", "metadata": {}}
{"text": "An adverse drug reaction reporting program in a community hospital .Qual Rev Bull 1988;14:336e40 .van der Hooft CS , Sturkenboom MC , van Grootheest K , et al .Adverse drug reaction - related hospitalisations : a nationwide study in the Netherlands .Drug Saf 2006;29:161e8 .Winterstein AG , Hatton RC , Gonzalez - Rothi R , et al .Identifying clinically significant preventable adverse drug events through a hospital 's database of adverse drug reaction reports .Am J Health Syst Pharm 2002;59:1742e9 .Whipple JK , Quebbeman EJ , Lewis KS , et al .", "label": "", "metadata": {}}
{"text": "Ann Pharmacother 1994;28:655e8 .Lau HS , Florax C , Porsius AJ , et al .The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards .Br J Clin Pharmacol 2000;49:597e603 .Murff HJ , Patel VL , Hripcsak G , et al .Detecting adverse events for patient safety research : a review of current methodologies .J Biomed Inform 2003;36:131e43 .doi:10.1136/amiajnl-2011 - 000454 Review .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .To address the underreporting problem , alerting systems that can automati\u00ad cally detect ADEs in EHRs are potentially very valuable , and much research has been conducted to that end .\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Adverse drug events ( ADEs ) are heavily underreported in electronic health records ( EHRs ) .Alerting systems that are able to detect potential ADEs on the basis of patient - specific EHR data would help to mitigate this problem .When modeling data in semantic space , an important design decision concerns the size of the context window around an object of interest , which governs the scope of co - occurrence information that is taken into account and affects the composition of the resulting semantic space .", "label": "", "metadata": {}}
{"text": "A follow - up investigation is conducted to study the impact on predictive performance as increasingly more semantic spaces are included in the ensemble , demonstrating that accuracy tends to improve with the number of semantic spaces , albeit not monotonically so .Finally , a number of different strategies for combining the semantic spaces are explored , demonstrating the advantage of early ( feature ) fusion over late ( classifier ) fusion .Semantic space ensembles allow multiple views of ( sparse ) data to be captured ( densely ) and thereby enable improved performance to be obtained on the task of detecting ADEs in EHRs .", "label": "", "metadata": {}}
{"text": "\" They abstracted data regarding rule characteristics including type , accuracy , and rational \" [ 15].Honigman et al . also developed a program that combines four computer search methods , including text searching of the electronic medical record , to detect ADEs in outpatient settings[16].\" [ Show abstract ] [ Hide abstract ] ABSTRACT : BackgroundAntibiotics are the widely prescribed drugs for children and most likely to be related with adverse reactions .Record on adverse reactions and allergies from antibiotics considerably affect the prescription choices .Our results highlight that some type of antibiotics form different clusters , which insight is most helpful for the clinician to support better decision - making .", "label": "", "metadata": {}}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : We present and test the intuition that letters to the editor in journals carry early signals of adverse drug events ( ADEs ) .Surprisingly these letters have not yet been exploited for automatic ADE detection unlike for example , clinical records and PubMed .Part of the challenge is that it is not easy to access the full - text of letters ( for the most part these do not appear in PubMed ) .Also letters are likely underrated in comparison with full articles .Besides demonstrating that this intuition holds we contribute techniques for post market drug surveillance .", "label": "", "metadata": {}}
{"text": "We also involve natural language processing for feature definitions .Overall we achieve high accuracy in our experiments and our method also works well on a second new test set .Our results encourage us to further pursue this line of research .No preview \u00b7 Article \u00b7 Jan 2012 \u00b7 AMIA ...Annual Symposium proceedings / AMIA Symposium .AMIA Symposium The RMD_RUNS function will log10 transform peptide peak intensity , that is , peptide abundance data and determine if any LC - MS analyses in a peptide data set are statistical outliers .[ Matzke MM , et al . , 2011 .", "label": "", "metadata": {}}
{"text": "\" - Bioinformatics 2011Oct 15;27(20):2866 - 72 ] .SPANS is an approach to evaluate normalization strategies , which includes the peptide selection component associated with the derivation of normalization values .Our approach evaluates the effect of normalization on the between - group variance structure in order to identify the most appropriate normalization methods that improve the structure of the data without introducing bias into the normalized peak intensities .The SPANS protocol was implemented in Java and all statistical methods were performed using MatLab \u00ae 2011a .[ Webb - Robertson BJM , et al . , 2011 .", "label": "", "metadata": {}}
{"text": "A Statistical Protocol for the Selection of Appropriate LC - MS Proteomics Peptide Dataset Normalizations .-Proteomics 2011 11(24):4736 - 41 ] .Quantification of sequence abundance in RNA - Seq experiments is often conflated by protocol - specific sequence bias .The exact sources of the bias are unknown , but may be influenced by PCR amplification , or differing primer affinities and mixtures , for example .The result is decreased accuracy in many applications , such as de novo gene annotation and transcript quantification .We developed a new method to measure and correct for these influences using a simple graphical model .", "label": "", "metadata": {}}
{"text": "We evaluated our method on several data sets , and by multiple criteria , demonstrating that it effectively decreases bias and increases uniformity .Additionally , our theoretical and empirical results show that the method is unlikely to have any effect on unbiased data , suggesting it can be applied with little risk of spurious adjustment .Compression of next - generation sequencing reads aided by highly - efficient de novo assembly .We present Quip , a lossless compression algorithm for next - generation sequencing data in the FASTQ and SAM / BAM formats .In addition to implementing reference - based compression , we have developed , to our knowledge , the first assembly - based compressor , using a novel de novo assembly algorithm .", "label": "", "metadata": {}}
{"text": "Read sequences are then stored as positions within the assembled contigs .2012 Aug 16 Our site uses cookies to improve your experience .You can find out more about our use of cookies in About Cookies , including instructions on how to turn off cookies if you wish to do so .By continuing to browse this site you agree to us using cookies as described in About Cookies .Notice : Wiley Online Library will be unavailable on Saturday 27th February from 09:00 - 14:00 GMT / 04:00 - 09:00 EST / 17:00 - 22:00 SGT for essential maintenance .", "label": "", "metadata": {}}
{"text": "Abstract .Ectotherms are considered to be particularly vulnerable to climate warming .Descriptions of habitat temperatures and predicted changes in climate usually consider mean monthly , seasonal or annual conditions .Ectotherms , however , do not simply experience mean conditions , but are exposed to daily fluctuations in habitat temperatures .Here , we highlight how temperature fluctuation can generate ' realized ' thermal reaction ( fitness ) norms that differ from the ' fundamental ' norms derived under standard constant temperatures .Using a mosquito as a model organism , we find that temperature fluctuation reduces rate processes such as development under warm conditions , increases processes under cool conditions , and reduces both the optimum and the critical maximum temperature .", "label": "", "metadata": {}}
{"text": "Such effects of daily temperature dynamics have generally been ignored in the climate change literature .If you ca n't find a tool you 're looking for , please click the link at the top of the page to \" Go to old article view \" .Alternatively , view our Knowledge Base articles for additional help .Your feedback is important to us , so please let us know if you have comments or ideas for improvement .Introduction .These curves are often used to assess the sensitivity of ectotherm species to climate warming , sometimes considering individual life - history traits ( Amarasekare & Savage , 2012 ) , or composite fitness metrics such as the intrinsic rate of increase ( Deutsch et al . , 2008 ; Tewksbury et al .", "label": "", "metadata": {}}
{"text": ", 2012 ; Ribeiro et al ., 2012 ) or in thermal performance breadth ( Angert et al . , 2011 ) as a result of changing thermal environments .In addition , studies use measures such as the Thermal Safety Margin ( TSM ) , which defines the amount of warming possible before habitat temperatures ( T h ) reach and ultimately exceed the thermal optimum ( T o ) ( Deutsch et al . , 2008 ; Huey et al ., 2009 ; Hoffmann , 2010 ; Hofmann & Todgham , 2010 ; Clusella - Trullas et al . , 2011 ; Bonebrake & Deutsch , 2012 ; Krenek et al .", "label": "", "metadata": {}}
{"text": "Effect of daily temperature variation on ectotherm fitness .Fundamental performance curve ( relative fitness ; black line ) under constant temperature conditions and realized performance when appropriate daily temperature variation is considered ( grey line ) for the temperate terrestrial insect Muscidifurax zaraptor .Gray data point and horizontal grey line represent the mean habitat temperature ( T h ) and the average habitat temperature range , respectively .CT min , critical minimum temperature ; ( r ) T o , ( realized ) optimum temperature ; ( r)CT max , ( realized ) critical maximum temperature ; and ( r)TSM , ( realized ) thermal safety margin .", "label": "", "metadata": {}}
{"text": "However , temperature is highly dynamic ( Geerts , 2003 ; Paaijmans et al . , 2010 ) and numerous studies provide evidence of insects and other ectotherms ' integrating ' the effects of temperature during the daily cycle ( Liu et al . , 1995 ; Kingsolver et al ., 2009 ; Paaijmans et al . , 2010 ; Bozinovic et al . , 2011 ; Duncan et al . , 2011 ; Estay et al . , 2011 ; Folguera et al .Accordingly , short - term environmental variance has the potential to affect life - history traits and fitness above and beyond the effects of mean temperatures alone ( Ruel & Ayres , 1999 ; Martin & Huey , 2008 ; Folguera et al . , 2009 , 2011 ; Terblanche et al . , 2010 ; Bozinovic et al . , 2011 ; Clusella - Trullas et al .", "label": "", "metadata": {}}
{"text": "Here , using the mosquito Anopheles stephensi as a model organism , we ask whether the ' fundamental ' thermal reaction norms established under constant temperature conditions differ from those derived under more natural fluctuating temperatures .We illustrate how daily temperature fluctuations can lower both the optimum and critical maximum temperatures of thermal reaction norms .We then generalize these effects for a range of terrestrial insects using a rate summation modeling approach .This analysis reveals that daily temperature fluctuations will tend to reshape the fundamental fitness curve , reducing the temperature optimum and hence , the TSM .", "label": "", "metadata": {}}
{"text": "Materials and methods .Empirical studies exploring the effects of temperature variation on life - history traits .Temperature was monitored closely with temperature loggers ( OM-62 ; Omega , Stamford , CT , USA ) at 15 min intervals .To exclude the potential effect of incubator , incubator programs were changed between experiments ( e.g. , an incubator running at a low but constant temperature was then programmed to fluctuate around a high mean temperature , etc . ) .Immature An .A small water volume was chosen to ensure water temperature tracked the temperature in the incubators .", "label": "", "metadata": {}}
{"text": "Immatures were placed back in clean water that was stored overnight at the respective temperature , to avoid temperature variation due to daily changing of the water .Larvae were fed 0.3 mg of tropical fish food ( Tetrafin \u00ae ) per larva per day .Emerged adult mosquitoes were counted ( at the end of the night cycle ) and removed .Daily development rate ( reciprocal of time until adult emergence ) and survival to adult were measured during different temperature experiments , with six replicate cups per temperature treatment .Utilizing these general methods we conducted a suite of experiments to explore effects of mean temperature and daily temperature variation on specific aspects of thermal reaction norms .", "label": "", "metadata": {}}
{"text": "This temperature range was selected on the basis of pilot data and those published for An . gambiae ( Bayoh & Lindsay , 2003 ) .In our experiments , we define CT min and CT max more ecologically as those temperatures at which mosquito survival through to adulthood is zero ( which could still mean larvae surviving for many days but failing to emerge from pupae ) .This measure is not equivalent to the traditional upper or low lethal temperatures , which again tend to be defined based on mortality following single short - term exposures to temperature extremes ( Piyaphongkul et al .", "label": "", "metadata": {}}
{"text": "Effects of fluctuation at different points on the reaction norm .These temperature ranges are commonly experienced by anopheline mosquitoes ( Paaijmans et al .Effects of temperature variation on the temperature optimum .Here , we investigated the effects of a DTR of 12 \u00b0 C around subtly different means of 28 , 30 , and 32 \u00b0 C to examine more precisely whether daily fluctuations in temperature affected the optimum temperature for development and survival .For this set of experiments , we ran a full factorial generalized linear model ( GZLM ) analysis to assess how mean temperature , diurnal temperature fluctuation , and replicate influence larval development time ( days ) and the number of emerging adult mosquitoes .", "label": "", "metadata": {}}
{"text": "We assessed goodness of fit of the final models through model deviance / d .f. scores and model residuals .Reduced models were achieved by eliminating the highest order , nonsignificant interactions through backward elimination .All post hoc tests were Bonferroni corrected , and analyses were run in spss 20.0 ( IBM Corporation , Armonk , NY , USA ) .In addition , for the temperature optima experiment , development times were transformed to meet the assumption of normality .Effects of temperature variation on the critical maximum temperature .To investigate the effects of temperature variation on CT max , we measured survival at a range of high mean temperatures with and without different DTRs .", "label": "", "metadata": {}}
{"text": "In addition , we ran a further assay to examine the impact of smaller fluctuations ( DTRs of 3 , 5 , and 7 \u00b0 C ) around 35 \u00b0 C only .Our aim in these experiments was to determine the temperature combinations at which mosquito survival through to adulthood was zero .Theoretical analysis of thermal safety margins under current and future climate conditions .We now extend our approach to explore the effects of temperature fluctuation on the TSM of 29 terrestrial insect species .These species represent a subset of those presented in an earlier study by Deutsch et al .", "label": "", "metadata": {}}
{"text": "We used rate summation ( Liu et al . , 1995 ) to accumulate fitness rates at hourly intervals using the ' fundamental ' fitness curves for each species and the relevant diurnal temperature cycles for the local environment .This approach generates a ' realized ' thermal fitness curve based on the average daily temperature variation experienced by the insect in nature .We then compare the TSMs based on the fundamental thermal fitness curve with TSMs based on the realized curves .The asymmetric thermal curves for relative insect fitness ( the intrinsic rate of increase scaled to 1 as a maximum ) were calculated using a Gaussian quadratic function described by Deutsch et al .", "label": "", "metadata": {}}
{"text": "However , rather than calculating the critical temperature ( CT min ) from the quadratic function , the authors provided an operational definition of CT min .While this was appropriate for their study , for our rate summation approach we needed the full thermal fitness curves so we refitted Gaussian quadratic models to the empirical data from the original source literature .When the original fitness data were presented as a figure only , the figure was digitized using Engauge Digitizer to obtain the values .To increase the robustness of our model , we used two additional criteria : ( 1 ) there should be at least three fitness data points below T o and ( 2 ) the relative fitness value of one of these data points had to be lower than 0.5 .", "label": "", "metadata": {}}
{"text": "Mean monthly minimum and maximum temperature surfaces were generated from the period 1960 - 1990 ( referred to as contemporary temperatures ) using weather station records containing at least 10 years of data in this period .These surfaces were imported into ESRI tm ArcGIS ArcView 9.3 and used to obtain the climatic data for the geographical locations of the 29 insect species .This climate model and scenario is one of the several possible combinations but has been used in a number of recent ecological studies examining possible effects of climate change ( Heikkinen et al . , 2010 ; Lassalle et al . , 2010 ; Milanovich et al . , 2010 ; Jaramillo et al .", "label": "", "metadata": {}}
{"text": "Applying some form of seasonal constraint is consistent with other studies ( e.g. , Clusella - Trullas et al . , 2011 ) , but differs from the original approach of Deutsch et al .( 2008 ) , who considered year - round mean temperatures .How habitat temperature is characterized will influence the value of the TSM .However , our focus here is not on the absolute values of TSM but the relative change that results from the use of fluctuating temperatures compared with mean temperatures .The air temperature was modeled at 1 h intervals using the contemporary and the forecast minimum and maximum temperatures , assuming a day length of 12 h. .", "label": "", "metadata": {}}
{"text": "The rate summation approach generates a realized thermal fitness curve with a realized optimum temperature ( r T o ) , based on the average daily temperature variation experienced by the insect in nature .We compared TSMs based on the fundamental fitness curves ( T o - T h ) with those based on the realized fitness curves ( r T o - T h ) .All model calculations and figures were produced in the statistical package R ( R Development Core Team , 2012 ) .Results .Empirical studies .2 a and b ) .", "label": "", "metadata": {}}
{"text": "2 c and d ) .At the intermediate temperature ( 26 \u00b0 C ) , fluctuation had no significant effects relative to the baseline constant temperature .Figure 2 .Impact of constant and variable temperatures on insect life - history traits .( a , b ) Fundamental thermal reaction norm for ( a ) daily development rate and ( b ) survival of Anopheles stephensi mosquito immatures measured at 11 constant temperatures .The vertical error bars in all panels represent the standard error of the mean .Daily temperature variation also affected the estimate of the temperature optimum .", "label": "", "metadata": {}}
{"text": "This means that the temperature optimum in a real - world fluctuating environment ( what we call the ' realized ' optimum temperature , r T o ) will be lower than the ' fundamental ' optimum temperature ( T o ) estimated under constant conditions .Similar patterns occurred with the critical maximum temperature , CT max ( Fig .3 a - c ) .At a constant temperature of 35 \u00b0 C , larvae survive through to adulthood ( Fig .Varying DTR around a single mean temperature of 35 \u00b0 C yielded similar results .With a DTR of 7 \u00b0 C , no mosquitoes survived to adult eclosion .", "label": "", "metadata": {}}
{"text": "3 d ) .Figure 3 .Impact of variable temperatures on the critical maximum temperature .2 b ) .( d ) Effect of smaller DTRs around a mean temperature of 35 \u00b0 C .Vertical error bars represent the standard error of the mean .Theoretical studies .We examined the consequences of daily temperature variation for 29 terrestrial insect species using rate summation ( i.e. , summing fitness at hourly intervals as temperature fluctuates across the standard fitness curve in line with the average DTR experienced by the insect ) .In Fig .1 , we present an illustrative example for one temperate species ( note fitness is scaled to 1 to enable comparisons of relative fitness ) .", "label": "", "metadata": {}}
{"text": "Commensurate with the lower temperature optimum , the TSM is reduced in the fluctuating environment from 16.6 to 13.5 \u00b0 C . .Extending this approach to the full set of species results in reductions in TSMs ranging from 0.8 to 4.5 \u00b0 C ( Fig .4 a ) .The decrease in TSM applies to all species across latitudes ; because daily temperature variation lowers the realized temperature optimum and brings it closer to the prevailing habitat temperature , we predict species to have increased sensitivity to climate warming .Figure 4 .Effects of daily temperature variation and climate warming on thermal safety margins across latitude .", "label": "", "metadata": {}}
{"text": "Open gray circles represent estimates based on the mean habitat temperature , black solid circles estimates based on the average habitat temperature range .The gray area represents the tropics .The increased sensitivity is confirmed by substituting the contemporary climate data with projections from the HadCM3 climate scenario for 2080 ( considering not only changes in mean temperature but also the forecast changes in temperature variation for species - specific locations , see Figure S1 ) .As expected , with warmer habitat temperatures across the board , the TSMs of all species are reduced .However , with mean temperatures and the fundamental fitness curves , only one of the TSMs was reduced to zero or below , indicating some remaining buffer against negative impacts on fitness for the majority of species .", "label": "", "metadata": {}}
{"text": "4 b ) .Discussion .Our empirical and theoretical investigations demonstrate that key elements of thermal sensitivity ( T o , CT max , TSM ) , as well as the overall shape of the thermal reaction norms , depend not only on mean temperatures but also on the extent of daily temperature variation .The empirical and theoretical effects of temperature variation follow a number of previous studies ( Siddiqui et al . , 1973 ; Worner , 1992 ; Liu et al . , 1995 ; Mironidis & Savopoulou - Soultani , 2008 ; Paaijmans et al . , 2010 ; Bozinovic et al .", "label": "", "metadata": {}}
{"text": ", 2012 ; Raffel et al . , 2013 ) and evolution ( Martin & Huey , 2008 ; Kingsolver et al ., 2009 ; Asbury & Angilletta , 2010 ) of ectotherm life - history traits ( and note that temporal variation in temperature can also affect hibernating endotherms ( Boyles & McKechnie , 2010 ) ) .The extent to which such effects derive from rate summation alone remains unclear .Additional physiological mechanisms such as production and breakdown of heat shock proteins ( McMillan et al . , 2005 ) could further exacerbate the influence of temperature variation , especially toward the extremes of thermal reaction norms .", "label": "", "metadata": {}}
{"text": ", 2009 ; Santos et al . , 2011 ; Piyaphongkul et al ., 2012 ; Ribeiro et al .Estimates of CT max are highly sensitive to the methodology used and can vary depending on factors such as heating rates , insect age , and body mass ( Bowler & Terblanche , 2008 ; Santos et al . , 2011 ; Ribeiro et al ., 2012 ) , as well as the specific response parameter studied ( Santos et al .The observed reduction in CT max under fluctuating temperature conditions adds another layer of complexity to accurately defining this critical parameter .", "label": "", "metadata": {}}
{"text": "A species ' vulnerability to climate change will depend on a range of factors , and unraveling the relative importance of these creates a number of research challenges ., 2011 ; Hamilton et al .In addition , while it is generally true that smaller terrestrial ectotherms conform to ambient temperature ( Stevenson , 1985a ) , certain ectotherms may limit temperature extremes via thermal behavior ( Stevenson , 1985b ; Huey et al ., 2012 ) and hence , modulate the short - term influence of temperature variability .In the longer term , ectotherms can potentially modify responses through genotypic adaptation and/or phenotypic plasticity ( Atkins & Travis , 2010 ; Chevin et al . , 2010 ) , further altering thermal reaction norms .", "label": "", "metadata": {}}
{"text": "How multiple reaction norms combine is unclear but given the potential for trade - offs , temperature optima for overall fitness might differ from those of individual traits .These issues notwithstanding , we follow the argument of Huey et al .( 2012 ) that thermal fitness curves provide a convenient , fundamental descriptor of how temperature influences fitness of ectotherms .In this regard , TSM represents a comparative metric to characterize sensitivity ( Deutsch et al . , 2008 ; Jaramillo et al ., 2009 ; Clusella - Trullas et al . , 2011 ; Krenek et al .", "label": "", "metadata": {}}
{"text": "Climate change can lead to phenological change , species ' range shifts and even extinction of plants and animals ( Easterling et al .Most studies to date use the standard fitness curves derived from constant temperature experiments combined with mean habitat temperatures to assess such climate - induced risks .Our results indicate that inclusion of daily temperature dynamics can generate substantial shifts in these fitness profiles .The general lowering of TSMs and CT max , together with the potential for altered ecological interactions under fluctuating temperature conditions ( e.g. , Duncan et al . , 2011 ; Hamilton et al .", "label": "", "metadata": {}}
{"text": "To better understand the role of environmental temperature , there is a clear need to integrate ecologically realistic thermal regimes into a wider range of empirical studies ( Rohr et al . , 2011 ; Niehaus et al ., 2012 ) , matching thermal regimes with the operative body temperatures experienced by organisms in the field .Acknowledgements .We thank Silvie Huijben for her help with R - coding , and Janet Teeple and Katey Glunt for assistance in the laboratory .This study was supported by a NSF - EID program grant ( # EF-0914384 ) .", "label": "", "metadata": {}}
{"text": "This project was also assisted by a grant from the Pennsylvania Department of Health using Tobacco Settlement Funds .The Department specifically disclaims responsibility for any analyses , interpretations or conclusions .The funders had no role in study design , data collection and analysis , decision to publish , or preparation of the manuscript .Ancillary .Article Information .DOI .Format Available .\u00a9 2013 The Authors .Global Change Biology published by John Wiley & Sons Ltd. .This is an open access article under the terms of the Creative Commons Attribution - NonCommercial License , which permits use , distribution and reproduction in any medium , provided the original work is properly cited and is not used for commercial purposes .", "label": "", "metadata": {}}
{"text": "Figure S1 .Mean temperatures and daily temperature ranges , and changes therein as a result of climate warming .( a ) mean habitat temperature ( T h ; as recorded in the 1960 - 1990 period ) and daily temperature range ( DTR ) , and ( b ) the change in mean habitat temperature ( T h ) and DTR as a result of warming .The gray area represents the tropics .Please note : Wiley - Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors .Any queries ( other than missing content ) should be directed to the corresponding author for the article .", "label": "", "metadata": {}}
{"text": "Amarasekare P , Savage V ( 2012 )A framework for elucidating the temperature dependence of fitness .American Naturalist , 179 , 178 - 191 .Angert AL , Sheth SN , Paul JR ( 2011 )Incorporating population - level variation in thermal performance into predictions of geographic range shifts .Integrative and Comparative Biology , 51 , 733 - 750 .Bayoh MN , Lindsay SW ( 2003 )Effect of temperature on the development of the aquatic stages of Anopheles gambiae sensu stricto ( Diptera : Culicidae ) .Bulletin of Entomological Research , 93 , 375 - 381 .", "label": "", "metadata": {}}
{"text": "The mean and variance of environmental temperature interact to determine physiological tolerance and fitness .Physiological and Biochemical Zoology , 84 , 543 - 552 .Clusella - Trullas S , Blackburn TM , Chown SL ( 2011 )Climatic predictors of temperature performance curve parameters in ectotherms imply complex responses to climate change .American Naturalist , 177 , 738 - 751 .Deutsch CA , Tewksbury JJ , Huey RB , Sheldon KS , Ghalambor CK , Haak DC , Martin PR ( 2008 )Impacts of climate warming on terrestrial ectotherms across latitude .Proceedings of the National Academy of Sciences , 105 , 6668 - 6672 .", "label": "", "metadata": {}}
{"text": "Temporal variation in temperature determines disease spread and maintenance in Paramecium microcosm populations .Proceedings of the Royal Society B - Biological Sciences , 278 , 3412 - 3420 .Estay SA , Clavijo - Baquet S , Lima M , Bozinovic F ( 2011 )Beyond average : an experimental test of temperature variability on the population dynamics of Tribolium confusum .Population Ecology , 53 , 53 - 58 .Folguera G , Bastias DA , Bozinovic F ( 2009 ) Impact of experimental thermal amplitude on ectotherm performance : adaptation to climate change variability ?Comparative Biochemistry and Physiology A - Molecular & Integrative Physiology , 154 , 389 - 393 .", "label": "", "metadata": {}}
{"text": "An experimental test of the role of environmental temperature variability on ectotherm molecular , physiological and life - history traits : implications for global warming .Comparative Biochemistry and Physiology A - Molecular & Integrative Physiology , 159 , 242 - 246 .Hamilton PT , Richardson JML , Govindarajulu P , Anholt BR ( 2012 )Higher temperature variability increases the impact of Batrachochytrium dendrobatidis and shifts interspecific interactions in tadpole mesocosms .Ecology and Evolution , 2 , 2450 - 2459 .Heikkinen RK , Luoto M , Leikola N et al .( 2010 )Assessing the vulnerability of European butterflies to climate change using multiple criteria .", "label": "", "metadata": {}}
{"text": "Huey RB , Deutsch CA , Tewksbury JJ , Vitt LJ , Hertz PE , \u00c1lvarez PH , Garland T ( 2009 )Why tropical forest lizards are vulnerable to climate warming .Proceedings of the Royal Society B : Biological Sciences , 276 , 1939 - 1948 .Huey RB , Kearney MR , Krockenberger A , Holtum JAM , Jess M , Williams SE ( 2012 )Predicting organismal vulnerability to climate warming : roles of behaviour , physiology and adaptation .Philosophical Transactions of the Royal Society B - Biological Sciences , 367 , 1665 - 1679 .", "label": "", "metadata": {}}
{"text": "PLoS ONE , 4 , e6487 .Jaramillo J , Muchugu E , Vega FE , Davis A , Borgemeister C , Chabi - Olaye A ( 2011 )Some like it hot : the influence and implications of climate change on coffee berry borer ( Hypothenemus hampei ) and coffee production in East Africa .PLoS ONE , 6 , e24528 .Kingsolver JG , Ragland GJ , Diamond SE ( 2009 ) Evolution in a constant environment : thermal fluctuations and thermal sensitivity of laboratory and field populations of Manduca sexta .Evolution , 63 , 537 - 541 .", "label": "", "metadata": {}}
{"text": "Global warming impacts and conservation responses for the critically endangered European Atlantic sturgeon .Biological Conservation , 143 , 2441 - 2452 .Liu SS , Zhang GM , Zhu J ( 1995 ) Influence of temperature variations on rate of development in insects : analysis of case studies from entomological literature .Annals of the Entomological Society of America , 88 , 107 - 119 .McMillan DM , Fearnley SL , Rank NE , Dahlhoff EP ( 2005 ) Natural temperature variation affects larval survival , development and Hsp70 expression in a leaf beetle .Functional Ecology , 19 , 844 - 852 .", "label": "", "metadata": {}}
{"text": "Environmental Entomology , 37 , 16 - 28 .Niehaus AC , Angilletta MJ , Sears MW , Franklin CE , Wilson RS ( 2012 )Predicting the physiological performance of ectotherms in fluctuating thermal environments .Journal of Experimental Biology , 215 , 694 - 701 .Paaijmans KP , Jacobs AFG , Takken W , Heusinkveld BG , Githeko AK , Dicke M , Holtslag AAM ( 2008 ) Observations and model estimates of diurnal water temperature dynamics in mosquito breeding sites in western Kenya .Hydrological Processes , 22 , 4789 - 4801 .Paaijmans KP , Blanford S , Bell AS , Blanford JI , Read AF , Thomas MB ( 2010 ) Influence of climate on malaria transmission depends on daily temperature variation .", "label": "", "metadata": {}}
{"text": "R Development Core Team ( 2012 ) R : A Language and Environment for Statistical Computing .R Foundation for Statistical Computing , Vienna , Austria .Raffel TR , Romansic JM , Halstead NT , McMahon TA , Venesky MD , Rohr JR ( 2013 ) Disease and thermal acclimation in a more variable and unpredictable climate .Nature Climate Change , 3 , 146 - 151 .Rohr JR , Raffel TR ( 2010 )Linking global climate and temperature variability to widespread amphibian declines putatively caused by disease .Proceedings of the National Academy of Sciences , 107 , 8269 - 8274 .", "label": "", "metadata": {}}
{"text": "The Canadian Entomologist , 105 , 145 - 156 .Terblanche JS , Nyamukondiwa C , Kleynhans E ( 2010 )Thermal variability alters climatic stress resistance and plastic responses in a globally invasive pest , the Mediterranean fruit fly ( Ceratitis capitata ) .Entomologia Experimentalis et Applicata , 137 , 304 - 315 . 2 Guorui Xu , Shuang Zhang , Yinghua Lin , Keming Ma , Context dependency of the density - body mass relationship in litter invertebrates along an elevational gradient , Soil Biology and Biochemistry , 2015 , 88 , 323 CrossRef .3 Simone Baldanzi , Nicolas F. Weidberg , Marco Fusi , Stefano Cannicci , Christopher D. McQuaid , Francesca Porri , Contrasting environments shape thermal physiology across the spatial range of the sandhopper Talorchestia capensis , Oecologia , 2015 CrossRef .", "label": "", "metadata": {}}
{"text": "5 Rosa A. S\u00e1nchez - Guill\u00e9n , Alex C\u00f3rdoba - Aguilar , Bengt Hansson , J\u00fcrgen Ott , Maren Wellenreuther , Evolutionary consequences of climate - induced range shifts in insects , Biological Reviews , 2015 , n / a Wiley Online Library .6 Gianluca Polgar , Tsung Fei Khang , Teddy Chua , David J. Marshall , Gross mismatch between thermal tolerances and environmental temperatures in a tropical freshwater snail : Climate warming and evolutionary implications , Journal of Thermal Biology , 2015 , 47 , 99 CrossRef .7 A. J. M. Tack , T. Mononen , I. Hanski , Increasing frequency of low summer precipitation synchronizes dynamics and compromises metapopulation stability in the Glanville fritillary butterfly , Proceedings of the Royal Society B : Biological Sciences , 2015 , 282 , 1806 , 20150173 CrossRef . 8", "label": "", "metadata": {}}
{"text": "9 Ronald W. Patra , John C. Chapman , Richard P. Lim , Peter C. Gehrke , Ramasamy M. Sunderam , Interactions between water temperature and contaminant toxicity to freshwater fish , Environmental Toxicology and Chemistry , 2015 , 34 , 8 , 1809 Wiley Online Library .10 Alex Richter - Boix , Marco Katzenberger , Helder Duarte , Mar\u00eda Quintela , Miguel Tejedo , Anssi Laurila , Local divergence of thermal reaction norms among amphibian populations is affected by pond temperature variation , Evolution , 2015 , n / a Wiley Online Library .11 Dominiek Vangansbeke , Duc Tung Nguyen , Joachim Audenaert , Ruth Verhoeven , Bruno Gobin , Luc Tirry , Patrick De Clercq , Prey consumption by phytoseiid spider mite predators as affected by diurnal temperature variations , BioControl , 2015 CrossRef .", "label": "", "metadata": {}}
{"text": "13 Shannon L. LaDeau , Brian F. Allan , Paul T. Leisnham , Michael Z. Levy , Karl Evans , The ecological foundations of transmission potential and vector - borne disease in urban landscapes , Functional Ecology , 2015 , 29 , 7 , 889 Wiley Online Library .14 Tracey D. Tuberville , Kimberly M. Andrews , Jinelle H. Sperry , Andrew M. Grosse , Use of the NatureServe Climate Change Vulnerability Index as an Assessment Tool for Reptiles and Amphibians : Lessons Learned , Environmental Management , 2015 CrossRef .15 Sylvain Pincebourde , J\u00e9r\u00f4me Casas , Warming tolerance across insect ontogeny : influence of joint shifts in microclimates and thermal limits , Ecology , 2015 , 96 , 4 , 986 Wiley Online Library .", "label": "", "metadata": {}}
{"text": "17 Jeanne A. Zeh , Melvin M. Bonilla , Eleanor J. Su , Michael V. Padua , Rachel V. Anderson , David W. Zeh , Constant diurnal temperature regime alters the impact of simulated climate warming on a tropical pseudoscorpion , Scientific Reports , 2014 , 4 CrossRef .18 George K. Mironidis , Development , survivorship and reproduction of Helicoverpa armigera ( Lepidoptera : Noctuidae ) under fluctuating temperatures , Bulletin of Entomological Research , 2014 , 104 , 06 , 751 CrossRef .19 Sabrina Clavijo - Baquet , Francisca Boher , Lucia Ziegler , Sebasti\u00e1n I. Martel , Sergio A. Estay , Francisco Bozinovic , Differential responses to thermal variation between fitness metrics , Scientific Reports , 2014 , 4 CrossRef .", "label": "", "metadata": {}}
{"text": "1 School of Computer Science and Technology , Xidian University , Xi'an 710071 , China 2 College of Information Technology , Hebei Normal University , Shijiazhuang 050016 , China .Received 23 September 2012 ; Revised 16 December 2012 ; Accepted 22 December 2012 .Academic Editor : Jiman Hong .Copyright \u00a9 2013 Shuai Fu et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .Abstract .Clustering provides an effective way to prolong the lifetime of wireless sensor networks .", "label": "", "metadata": {}}
{"text": "In this paper , we design a method to mitigate the uneven energy dissipation problem .Considering the relaying load undertaken by each cluster , we use the network topology and energy consumption to calculate a cluster radius for obtaining the intercluster energy balancing .A new cluster - leader election algorithm is proposed wherein the task of a single cluster head is separated to two nodes so that the critical nodes in each cluster will not exhaust their power so quickly .Furthermore , cross - level data transmission is used to prolong network lifetime .Extensive simulation experiments are carried out to evaluate the method with several performance criteria .", "label": "", "metadata": {}}
{"text": "Abstract .Background .In this study we compared how many participants recovered after each treatment .Method .We used logistic regression modelling to compare treatments .Results .The percentages ( number / total ) meeting trial criteria for recovery were 22 % ( 32/143 ) after CBT , 22 % ( 32/143 ) after GET , 8 % ( 12/149 ) after APT and 7 % ( 11/150 ) after SMC .Similar proportions met criteria for clinical recovery .There was no significant difference between APT and SMC .Similar proportions recovered in trial subgroups meeting different definitions of the illness .", "label": "", "metadata": {}}
{"text": "This study confirms that recovery from CFS is possible , and that CBT and GET are the therapies most likely to lead to recovery .Key words : Chronic fatigue syndrome , cognitive behaviour therapy , graded exercise therapy , randomized control trial , recovery .Introduction .Chronic fatigue syndrome ( CFS ) is a disabling disorder of unknown cause , with a prevalence of between 0.4 % and 2.5 % in the UK population ( Prins et al .2006 ) .Myalgic encephalomyelitis ( ME ) is thought by some researchers to be the same disorder and by others as different with separate diagnostic criteria ( Prins et al .", "label": "", "metadata": {}}
{"text": "Common symptoms of CFS include fatigue , painful muscles and joints , poor concentration and sleep disturbance ; these symptoms do not remit with rest and are made worse by activity .Established treatments for CFS include the rehabilitative therapies of cognitive behaviour therapy ( CBT ) and graded exercise therapy ( GET ) ( NICE , 2007 ) .Several meta - analyses of these therapies indicate moderate benefit from these treatments ( Edmonds et al .2004 ; Malouff et al .2008 ; Price et al .2008 ; Castell et al .2011 ) .Although the PACE trial found that many patients improved with CBT and GET , the question of how many patients recovered remains unanswered .", "label": "", "metadata": {}}
{"text": "However , there have been no published reports comparing the proportions recovered after CBT with those achieved after other treatments .Before we can determine the proportions recovered we need an operational definition of recovery itself .An ideal definition remains uncertain , as is the case for other conditions , such as low back pain ( Kamper et al .2011 ) .Measurement of recovery could involve many domains .Within the trial context these could include : no longer meeting trial eligibility criteria , not having significant symptoms , not being disabled by the illness , and regarding one 's health as having improved considerably .", "label": "", "metadata": {}}
{"text": "1991 ; Tyrrell , 1994 ; Reeves et al .2003 ) .Creating criteria for recovery from domains that are measured on a continuum requires the setting of operational thresholds based on population studies or trial eligibility criteria ( Powell et al .2004 ; Knoop et al .2007 ; Malouff et al .2008 ) .In this context it is important to note that recovery does not mean being free of all symptoms ; population studies show that the average person in the UK reports a mean of four symptoms in any 2-week period ( McAteer et al .", "label": "", "metadata": {}}
{"text": "The three most common symptoms reported were fatigue , headache and joint pain ; symptoms consistent with CFS ( McAteer et al .2011 ) .Recovery may be taken to imply that the patient has made a transition from ill health to remission and also is at little risk of recurrence ( Nisenbaum et al .2003 ) .Although we can measure remission , we can not be certain of the risk of recurrence without long - term follow - up ; we therefore use the term ' recovery ' in this paper to mean recovery from the current episode of the illness .", "label": "", "metadata": {}}
{"text": "Method .The PACE trial recruited 641 participants from six secondary care CFS clinics in England and Scotland , allocated randomly to one of four treatment groups , with a final follow - up 52 weeks after randomization ( White et al .2007 , 2011 ) .All participants met the Oxford criteria for CFS ( Sharpe et al .1991 ) .The four trial treatment arms were : SMC alone delivered by specialist CFS doctors , SMC plus APT delivered by occupational therapists , SMC plus CBT delivered by clinical psychologists , and SMC plus GET delivered by physiotherapists .", "label": "", "metadata": {}}
{"text": "They also prescribed medicines to help with symptoms such as insomnia and pain , or advised general practitioners ( GPs ) on which medicine was appropriate .If a participant was randomized to this treatment alone , they were also encouraged to use self - help management that made most sense to them .APT involved carefully matching activity levels to the amount of energy available .Therapists worked with participants in this group to help monitor activity and symptoms , aiming to improve quality of life and create the best conditions for natural remission .CBT involved examining how thoughts , behaviour and symptoms interact with each other .", "label": "", "metadata": {}}
{"text": "GET involved gradually increasing physical activity to improve fitness and get the body used to activity again .Therapists helped participants in this group to work out a basic activity routine and slowly build up the amount of exercise ( White et al .2007 , 2011 ) .Domains , measures and criteria for defining recovery .We chose domains for defining recovery on the basis of the previous literature and the measures available from the trial .The thresholds defining our criteria for recovery on each domain were based either on population normal ranges , case definitions or trial entry criteria .", "label": "", "metadata": {}}
{"text": "2007 ) before the analysis , as explained below .Fatigue : the Chalder Fatigue Questionnaire ( CFQ ) .The 11-item CFQ measured the severity of symptomatic fatigue , rated by the participant , and was one of the primary outcomes of the trial ( Chalder et al .1993 ) .This showed a population mean ( s.d . )Likert score of 14.2 ( 4.6 ) out of a maximum score of 33 .We therefore considered a score of 18 ( highest integral score below the mean plus 1 s. d . ) or less as within the normal range for fatigue .", "label": "", "metadata": {}}
{"text": "The SF-36 physical function subscale , rated by the participants , was the other primary outcome from the trial ( McHorney et al .1993 ) .The scale asks about 10 aspects of physical function , such as the ability to walk 100 m , with three possible answers : not limited , limited a little , and limited a lot .This provides a derived score that ranges from worst ( 0 ) to best possible function ( 100 ) .We changed our original protocol 's threshold score for being within a normal range on this measure from a score of 85 to a lower score as that threshold would mean that approximately half the general working age population would fall outside the normal range .", "label": "", "metadata": {}}
{"text": "1999 ) .We derived a mean ( s.d . ) score of 84 ( 24 ) for the whole sample , giving a normal range of 60 or above for physical function .CFS case definition : Oxford criteria .This was the definition of CFS used to define eligibility for participation in the trial .CFS case definition : the International ( Centers for Disease Control and Prevention , CDC ) criteria .For the purposes of this study , the four or more symptoms needed to be present within the previous week of the assessment date , rather than the previous 6 months ( Reeves et al .", "label": "", "metadata": {}}
{"text": "To meet the first criterion for severity , participants had to have abnormal levels of fatigue , which we took to be the trial entry eligibility criteria for the CFQ , and abnormal levels of physical function ( as above ) ( White et al .2007 ) .ME case definition : the London criteria .Research assessors judged whether participants met the London criteria for ME at 52 weeks ( Tyrrell , 1994 ) .To standardize thresholds for severity with other case definitions , participants also had to meet trial entry eligibility criteria for the CFQ and abnormal levels of physical function ( as above ) ( White et al .", "label": "", "metadata": {}}
{"text": "Overall change in health : the Clinical Global Impression ( CGI ) change score .The self - rated CGI change score ( range 1 - 7 ) provided a participant - rated global measure of overall health change , not just change in CFS ( Guy , 1976 ) .The CGI change scale was also rated by the SMC doctor at the 52-week review .Composite definitions of recovery .We operationalized two composite definitions of recovery : ( 1 ) trial recovery from CFS , and ( 2 ) clinical recovery from the illness , however it was defined .", "label": "", "metadata": {}}
{"text": "Analysis .We reported descriptive statistics ( percentage and frequency ) in each treatment arm for each individual domain of recovery .The cumulative hierarchy of clinical recovery was then applied as the trial definition of recovery combined with not meeting criteria for either the International ( CDC ) definition of CFS or the London criteria for ME .We calculated the number needed to treat ( NNT ) for one extra participant to recover by dividing 100 by the proportion recovering after either CBT or GET minus the proportion recovering after SMC , rounded up to the nearest whole number .", "label": "", "metadata": {}}
{"text": "We then used logistic regression to compare the odds of recovery between trial arms , using the originally hypothesized comparison groups : APT v .SMC , CBT v .SMC , GET v .SMC , APT v .CBT and APT v. GET ( White et al .2011 ) .Resulting odds ratios ( ORs ) and 95 % confidence intervals ( CIs ) were adjusted for the stratification variables of centre , meeting International ( CDC ) criteria at baseline , meeting the London definition of ME at baseline , and having a depressive illness at baseline .", "label": "", "metadata": {}}
{"text": "We studied 640 participants ( excluding one participant who withdrew consent after the study ) .The mean ( s.d . ) age was 38 ( 12 ) years , 77 % were female , and 93 % were Caucasian .All participants met the Oxford criteria for CFS ; 67 % of participants also met the International ( CDC ) criteria for CFS and 51 % met the London criteria for ME ( White et al .2011 ) .The median ( interquartile range , IQR ) duration of illness was 32 ( 16 - 68 ) months , 47 % had a co - morbid psychiatric condition at randomization ( 33 % depressive disorder ) .", "label": "", "metadata": {}}
{"text": "Table 1 a shows the individual criteria for recovery at 52 weeks .Whatever the domain , the largest proportions of participants recovering had received either CBT or GET .Overall , the largest proportions of participants meeting criteria for recovery were those who no longer met criteria for ME , followed by the Internationally defined criteria for CFS , and then the Oxford - defined criteria for CFS .Table 1 b shows the hierarchical , cumulative definitions for both trial and clinical recovery .As each additional criterion was added , the proportions meeting criteria for recovery generally were reduced .", "label": "", "metadata": {}}
{"text": "Some data were missing for 6 % of those receiving APT and SMC and 11 % for those in receipt of CBT and GET .The NNT for one extra participant to achieve trial recovery was 7 for both CBT and GET .The proportions meeting criteria for clinical recovery from the illness were very similar to the proportions meeting the trial definition for recovery ( Table 1 b ) .Although it seemed that slightly smaller proportions had recovered from the illness as a whole , when the criterion ' not meeting the London criteria for ME ' was applied , we found that the differences were due to missing data rather than to change in recovery status .", "label": "", "metadata": {}}
{"text": "Table 2 shows the proportions who met the trial definition of recovery in subgroups that met alternative definitions of CFS or ME at baseline .The pattern of results was very similar to those for all participants ; CBT and GET were associated with the largest proportions of participants recovered .Composite criteria for trial recovery in subgroups meeting alternative definitions of CFS or ME at baseline .Table 3 shows that odds of trial definitions of recovery after either CBT or GET were more than three times those after either APT or SMC .There was no significant difference between APT and SMC .", "label": "", "metadata": {}}
{"text": "Discussion .We found that CBT and GET were both significantly more likely than APT and SMC to be associated with recovery at 52 weeks , even when using a conservative definition of recovery .Between a fifth and a quarter of participants were recovered by 52 weeks after either CBT or GET , with an NNT of seven .A similar pattern was seen in the two subgroups meeting alternative definitions for CFS and ME at entry into the trial .The main limitation of this analysis is the absence of a generally agreed measure of recovery .We addressed this by using multiple domains of health and disability .", "label": "", "metadata": {}}
{"text": "Alternative domains could have been used , such as return to work or objective measures of physical activity .Return to work is not , however , an appropriate measure of recovery if the participant was not working before their illness and is influenced by other factors such as the job market .We did not include any measures of mood in our domains of recovery as mood is not part of the definition of the illness .The amount of missing outcome data was greater after CBT and GET than after APT and SMC , but the percentages missing were small enough not to warrant sensitivity analyses , particularly because all but 33 ( 5 % ) participants contributed some data .", "label": "", "metadata": {}}
{"text": "The assessments of caseness ( CDC , London and Oxford criteria ) relied on a mixture of self - ratings and research assistant assessments , making some observer bias possible .We changed some of the thresholds for measuring recovery from those of the original protocols ( White et al .2007 ) ; we made the changes before analysis and to more accurately reflect recovery .Our finding that only 7 % recovered after the minimal treatment of SMC , exactly the same proportion as the median recovery rate found without treatment ( Cairns & Hotopf , 2005 ) , supports these revised thresholds .", "label": "", "metadata": {}}
{"text": "How do these results compare with previous studies ?We are not aware of any previous studies that have compared comprehensively defined recovery between different treatments .Two studies of recovery in adults after CBT found similar proportions in recovery : 23 % and 24 % ( Deale et al .2001 ; Knoop et al .2007 ) , compared with 22 % in the PACE trial .One of these studies had a 5-year follow - up period rather than the 1 year of our study , and the majority had received further treatment in those extra 4 years , all patients being treated at one specialist CFS centre ( Deale et al .", "label": "", "metadata": {}}
{"text": "The other study used similar criteria and domains for recovery ( Knoop et al .2007 ) , but the definition for normal range used was the more liberal population mean \u00b12 s. d .rather than the more conservative 1 s.d .that we used ; the treatment was delivered by therapists in one specialist CFS centre and outside of a trial setting .A meta - analysis of randomized controlled trials of CBT for CFS reported that a mean of 50 % of the patients improved to the point of no longer being clinically fatigued ( Malouff et al .", "label": "", "metadata": {}}
{"text": "A 2-year follow - up study after an educational intervention to encourage GET found that 55 % of the treated patients no longer fulfilled trial criteria for CFS ( Powell et al .2004 ) .Our finding that 22 - 56 % of participants met various composite or single criteria for recovery or improvement a year after starting either CBT or GET is therefore consistent with previously published studies .The NNT of 7 for recovery after both CBT and GET is within the range of the effects found for drug treatments in both general medical and psychiatric conditions ( Leucht et al .", "label": "", "metadata": {}}
{"text": "Although only 22 % recovered after either CBT or GET , if different participants recovered after CBT than after GET , then the proportion recovering after either treatment would be larger than 22 % , but not larger than 39 % .Recovery after CBT may be better in adolescents ( Nijhof et al .2012 ) .The 7 % and 8 % recovered after both APT and SMC were similar to the 7 % reported in a systematic review after no treatment , suggesting a lack of efficacy of these treatments ( Cairns & Hotopf , 2005 ) .", "label": "", "metadata": {}}
{"text": "Patients who have either CFS or ME characterized by a principal complaint of fatigue , and who are attending out - patient clinics , should therefore be offered either CBT or GET to provide the best chance of recovery with these treatments .As a little more than a fifth of participants treated with CBT or GET had recovered a year after starting treatment , we still need to consider ways of enhancing the effectiveness of these treatments .Another approach may be to offer both CBT and GET in series .A different approach would be to identify the factors that mediate the effect of these treatments , with the aim of optimizing their effectiveness ; the mediation analysis of the PACE data is under way .", "label": "", "metadata": {}}
{"text": "2011 ) .Finally , we also need to develop additional forms of treatment .In conclusion , recovery from CFS is more likely to occur when CBT or GET is added to SMC than after adding APT or giving SMC by itself .The relatively small proportion of recovered patients may reflect the heterogeneity of CFS ; it should also spur us on both to enhance currently available therapies and to develop new and better treatments .Acknowledgements .The funders of the PACE trial were : the UK Medical Research Council , the Department of Health for England , the Department for Work and Pensions , and the Scottish Chief Scientist Office .", "label": "", "metadata": {}}
{"text": "Trial registration : ISRCTN54285094 .Appendix .The PACE Trial Management Group .Declaration of Interest .P.D.W. has undertaken voluntary and paid consultancy work for the UK government and a reinsurance company .T.C. has received royalties from Sheldon Press and Constable & Robinson .M.S. has undertaken voluntary and paid consultancy work for the UK government and consultancy work for an insurance company , and has received royalties from Oxford University Press .References .Bowling A , Bond M , Jenkinson C , Lamping DL ( 1999 ) .Short Form 36 ( SF-36 ) Health Survey Questionnaire : which normative data should be used ?", "label": "", "metadata": {}}
{"text": "Journal of Public Health Medicine 21 , 255 - 270 [ PubMed ] .Cairns R , Hotopf M ( 2005 ) .A systematic review describing the prognosis of chronic fatigue syndrome .Occupational Medicine 55 , 20 - 31 [ PubMed ] .Castell BD , Kazantzis N , Moss - Morris RE ( 2011 ) .Cognitive behavioural therapy and graded exercise for chronic fatigue syndrome : a meta - analysis .Clinical Psychology : Science and Practice 18 , 311 - 324 .Cella M , Chalder T ( 2010 ) .Measuring fatigue in clinical and community settings .", "label": "", "metadata": {}}
{"text": "Cella M , Chalder T , White PD ( 2011 ) .Does the heterogeneity of chronic fatigue syndrome moderate the response to cognitive behaviour therapy ?Psychotherapy and Psychosomatics 80 , 353 - 358 [ PubMed ] .Chalder T , Berelowitz G , Hirsch S , Pawlikowska T , Wallace P , Wessely S ( 1993 ) .Development of a fatigue scale .Journal of Psychosomatic Research 37 , 147 - 153 [ PubMed ] .Deale A , Husain K , Chalder T , Wessely S ( 2001 ) .Long - term outcome of cognitive behaviour therapy versus relaxation therapy for chronic fatigue syndrome : a 5-year follow - up study .", "label": "", "metadata": {}}
{"text": "Edmonds M , McGuire H , Price JR ( 2004 ) .Exercise therapy for chronic fatigue syndrome .Cochrane Database of Systematic Reviews 3 , CD003200 .[PubMed ] .Guy W ( 1976 ) .ECDEU Assessment Manual for Psychopharmacology , pp .218 - 222 National Institute of Mental Health : Rockville , MD .Kamper SJ , Stanton TR , Williams CR , Maher CG , Hush JM ( 2011 ) .How is recovery from low back pain measured ?A systematic review of the literature .European Spine Journal 20 , 9 - 18 [ PMC free article ] [ PubMed ] .", "label": "", "metadata": {}}
{"text": "Is a full remission possible after cognitive behavioural therapy for chronic fatigue syndrome ?Psychotherapy and Psychosomatics 76 , 171 - 176 [ PubMed ] .Leucht S , Hierl S , Kissling W , Dold M , Davis JM ( 2012 ) .Putting the efficacy of psychiatric and general medicine medication into perspective : review of meta - analyses .British Journal of Psychiatry 200 , 97 - 106 [ PubMed ] .Malouff JM , Thorsteinsson EB , Rooke SE , Bhullar N , Schutte NS ( 2008 ) .Efficacy of cognitive behavioral therapy for chronic fatigue syndrome : a meta - analysis .", "label": "", "metadata": {}}
{"text": "McAteer A , Elliott AM , Hannaford PC ( 2011 ) .Ascertaining the size of the symptom iceberg in a UK - wide community - based survey .British Journal of General Practice 61 , e1-e11 [ PMC free article ] [ PubMed ] .McHorney CA , Ware JE , Raczek AE ( 1993 ) .The MOS 36-Item Short - Form Health Survey ( SF-36 ) : II .Psychometric and clinical tests of validity in measuring physical and mental health constructs .Medical Care 31 , 247 - 263 [ PubMed ] .", "label": "", "metadata": {}}
{"text": "Chronic Fatigue Syndrome / Myalgic Encephalomyelitis ( or Encephalopathy ) .Diagnosis and Management of CFS / ME in Adults and Children .Nijhof SL , Bleijenberg G , Uiterwaal CSPM , Kimpen JLL , van de Putte EM ( 2012 ) .Effectiveness of internet - based cognitive behavioural treatment for adolescents with chronic fatigue syndrome ( FITNET ) : a randomised controlled trial .Lancet 379 , 1412 - 1418 [ PubMed ] .Nisenbaum R , Jones JF , Unger ER , Reyes M , Reeves WC ( 2003 ) .A population - based study of the clinical course of chronic fatigue syndrome .", "label": "", "metadata": {}}
{"text": "[ PMC free article ] [ PubMed ] .Powell P , Bentall RP , Nye FJ , Edwards RHT ( 2004 ) .Patient education to encourage graded exercise in chronic fatigue syndrome 2-year follow - up of randomised controlled trial .British Journal of Psychiatry 184 , 142 - 146 [ PubMed ] .Price JR , Mitchell E , Tidy E , Hunot V ( 2008 ) .Cognitive behaviour therapy for chronic fatigue syndrome in adults .Cochrane Database of Systematic Reviews 3 , CD001027 .[PubMed ] .Prins JB , van der Meer JW , Bleijenberg G ( 2006 ) .", "label": "", "metadata": {}}
{"text": "Lancet 367 , 346 - 355 [ PubMed ] .Reeves WC , Lloyd A , Vernon SD , Klimas N , Jason LA , Bleijenberg G , Evengard B , White PD , Nisenbaum R , Unger ER ; International Chronic Fatigue Syndrome Study Group ( 2003 ) .Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution .BioMed Central Health Services Research 3 , 25 .[ PMC free article ] [ PubMed ] .A report- chronic fatigue syndrome : guidelines for research .Journal of the Royal Society of Medicine 84 , 118 - 121 [ PMC free article ] [ PubMed ] .", "label": "", "metadata": {}}
{"text": "Report from the National Task Force on Chronic Fatigue Syndrome ( CFS ) , PostViral Fatigue Syndrome ( PVFS ) and Myalgic Encephalomyelitis ( ME ) .Westcare : Bristol .van der Werf SP , Prins JB , Vercoulen JHMM , van der Meer JWM , Bleijenberg G ( 2001 ) .Identifying physical activity patterns in chronic fatigue syndrome using actigraphic assessment .Journal of Psychosomatic Research 49 , 373 - 379 [ PubMed ] .Comparison of adaptive pacing therapy , cognitive behaviour therapy , graded exercise therapy , and specialist medical care for chronic fatigue syndrome ( PACE ) : a randomised trial .", "label": "", "metadata": {}}
{"text": "White PD , Sharpe MC , Chalder T , DeCesare JC , Walwyn R ; PACE trial group ( 2007 ) .Protocol for the PACE trial : a randomised controlled trial of adaptive pacing , cognitive behaviour therapy , and graded exercise , as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome / myalgic encephalomyelitis or encephalopathy .BioMed Central Neurology 7 , 6 .[ PMC free article ] [ PubMed ] .Wiborg JF , Knoop H , Stulemeijer M , Prins JB , Bleijenberg G ( 2010 ) .", "label": "", "metadata": {}}
{"text": "The role of physical activity .Psychological Medicine 40 , 1281 - 1287 [ PubMed ] ( Received 19 June 2013 ; accepted 2 August 2013 ; online 26 September 2013 ) .The Japan Aerospace Exploration Agency ( JAXA ) started a high - quality protein crystal growth project , now called JAXA PCG , on the International Space Station ( ISS ) in 2002 .Using the counter - diffusion technique , 14 sessions of experiments have been performed as of 2012 with 580 proteins crystallized in total .Over the course of these experiments , a user - friendly interface framework for high accessibility has been constructed and crystallization techniques improved ; devices to maximize the use of the microgravity environment have been designed , resulting in some high - resolution crystal growth .", "label": "", "metadata": {}}
{"text": "In this article , the current status of JAXA PCG is discussed , and a rational approach to high - quality protein crystal growth in microgravity based on numerical analyses is explained .With regard to the X - ray diffraction analysis of protein crystals , the technique has been progressing over the last decades , from protein sample preparations and optimization of crystallization conditions to improvements in hardware and software for X - ray diffraction experiments and beyond .For X - ray crystallography , growing high - quality crystals is still the biggest hurdle ( McPherson , 1999 ) .", "label": "", "metadata": {}}
{"text": "Littke & John ( 1986 ) successfully obtained large lysozyme crystals in space in 1983 .Since then , many crystallization trials have been performed in microgravity ( Snell & Helliwell , 2005 ; Vergara et al . , 2005 ) .The many parameters that must be considered to judge whether space - grown crystals are superior to ground - grown ones make this a complicated analysis .On the other hand , Snell & Helliwell ( 2005 ) noted that the success rate of space experiments based on the criteria of improved diffraction resolution increased to 60 % when the analysis was limited to proteins that have flown four or more times .", "label": "", "metadata": {}}
{"text": "These depletion zones are considered to cause lower concentrations of protein and impurities on the surface of a crystal , resulting in high - quality crystal growth in microgravity .JAXA has aimed to regularly obtain high - quality crystals of useful proteins , so that microgravity crystallization can become one of the choices for researchers to consider in their experiment designs .For this purpose , a standard user - friendly experiment protocol was established to expedite the process from the acceptance of the samples to the launch .Also , numerical analyses were used to help establish a rational approach to increasing the probability of high - quality crystal growth through the enhancement of the PDZ and IDZ ( Tanaka et al .", "label": "", "metadata": {}}
{"text": ", 2012 ) .For transportation to and from the ISS , Russian Progress cargo ships and the Soyuz spacecraft have been used .Since 2008 , these crystallization experiments have been performed in the Protein Crystallization Research Facility ( PCRF ) on board the Japanese Experiment Module ' Kibo ' ( JEM ) ( Fig . 1 ) .Russian and Malaysian researchers have been participating in the experiments .Technical achievements in high - quality crystal growth and upgrades in the support system for users continue to advance , and , at present , if crystallization conditions are properly optimized , the reproducibility of high - quality crystal growth is a likely expectation .", "label": "", "metadata": {}}
{"text": "Two canisters are placed in the PCRF in JEM which can maintain a temperature of 293 K. .Rational approach for space experiments .PDZ and IDZ are considered to be formed around a growing crystal through the depression of the convective flow in microgravity ( Ot\u00e1lora et al . , 2001 ; Thomas et al . , 2000 ; Chernov et al . , 2001 ) .This can be explained using a simplified spherical model under steady conditions .The effects of PDZ can be expressed as the driving force ratio ( DFR ) and the effects of IDZ as the impurity ratio ( IR ) as described previously ( Tanaka et al .", "label": "", "metadata": {}}
{"text": "These ratios can be expressed as .where , R is the radius of a crystal , \u03b2 and \u03b2 i are kinetic coefficients for the protein and the impurity molecules , and D and D i are diffusion coefficients of the protein and the impurity molecules .From these equations it was concluded that DFR and IR are lower if R \u03b2 / D is larger .This means that PDZ and IDZ become more significant when a crystal grows larger ( R is larger ) , the uptake of the molecules into the crystal is faster ( \u03b2 is larger ) , and the diffusion of the molecules is slower ( D is smaller ) .", "label": "", "metadata": {}}
{"text": ", 2012 ) , if the usual size of the crystal in an X - ray diffraction experiment is around 0.1 mm on a side , then IR , not DFR , is significantly decreased .This implies that it is the IDZ that mainly affects high - quality crystal growth in microgravity .We introduced an equation to roughly estimate D ( Tanaka et al . , 2006 ) and used the experimental method to estimate \u03b2 ( Tanaka et al ., 2004 a ) .Using D and \u03b2 , we can estimate whether microgravity will positively affect each crystallization condition before performing a space experiment , and , if necessary , we may change a crystallization condition to one more suited to microgravity experiments .", "label": "", "metadata": {}}
{"text": "For the remaining 30 % of the proteins , crystals of improved quality could not be grown even when D / \u03b2 was less than 3 mm .The major causes for this were some differences in the sample lot used for the optimization of crystallization conditions and the one used in the space experiment .In some other cases , some deterioration of the space - grown crystals was caused by temperature surging up to almost 303 K during the retrieval flight from the ISS .The rates of microgravity experiments successfully obtaining higher - quality crystals , judged by higher maximum X - ray resolution , lower mosaicity and/or better morphology , in accordance with the D / \u03b2 value , are shown .", "label": "", "metadata": {}}
{"text": "Only the crystals for which the D / \u03b2 value could be calculated were used .To lower D / \u03b2 for maximizing the effects of microgravity on crystal growth , the first approach is to lower D , which can be achieved by preparing a high - viscosity crystallization solution using such additives as high - molecular - weight polyethylene glycol ( PEG ) .In a previous report ( Yamanaka et al . , 2011 ) , we found that the salt concentration in a PEG solution is crucial and that it is possible to estimate the lowest effective salt concentration .", "label": "", "metadata": {}}
{"text": "Using PEG in the crystallization solution has dramatically increased the quality of crystals grown in microgravity in these cases .Further purification of protein samples is effective in increasing \u03b2 .We applied high - performance ion - exchange column chromatography to a lysozyme sample to make it electrically homogeneous , and found out that it made \u03b2 several - fold larger ( Tanaka et al ., 2012 ) .We speculated that the impurities ( sometimes the same protein molecule with a different electric charge ) which were separated out by ion - exchange column chromatography might affect the crystal growth and decrease \u03b2 .", "label": "", "metadata": {}}
{"text": "Alpha - amylase has been crystallized in almost every JAXA PCG experiment as a benchmark protein and we have always obtained high - quality crystals from which X - ray diffraction was visually observed around 1.0 \u00c5 with improved morphologies .H - PGDS has been crystallized in space several times with various ligands since ; for some cases , we have successfully obtained a data set of X - ray diffraction of almost 1.0 \u00c5 resolution ( Tanaka et al . , 2011 ) .L - PGDS has been crystallized several times in space and has always yielded high - quality crystals by which we can obtain data sets of X - ray diffraction at around 1.0 \u00c5 resolution ( Inaka et al . , 2011 ) .", "label": "", "metadata": {}}
{"text": "Standard protocol of JAXA PCG .Based on the rational approach for space experiments , JAXA set a goal for high - quality protein crystal growth in microgravity and designed a standard protocol for the efficient performance of space experiments as shown in Fig .2 .Figure 2 Standard protocol for crystallization experiments of JAXA PCG .The protocol initiates with a proposal submitted by potential users .Based on the datasheet of protein information and crystallization history in a laboratory , the review board decides whether or not to accept the proposal .At present , only a protein which is stable at 293 K for more than several months is accepted since the PCRF is kept at this temperature .", "label": "", "metadata": {}}
{"text": "Therefore , we perform an acceptance test to check this with SDS - PAGE , native - PAGE , dynamic light scattering , high - performance liquid chromatography , and a crystallization check using the vapor - diffusion method .The last check is performed under the same conditions as the potential users ' crystallizations since most of the samples are crystallized in the laboratory by the vapor - diffusion method .We found that heterogeneity of the sample was often observed even though the crystal grew well .In such a case , we not only ask users to improve the sample preparation but also apply a further sample purification step using high - performance ion - exchange column chromatography in the hope of increasing \u03b2 .", "label": "", "metadata": {}}
{"text": "After the acceptance test , we convert the crystallization conditions from vapor - diffusion to counter - diffusion ( Garc\u00eda - Ruiz & Moreno , 1994 ; Garc\u00eda - Ruiz et al . , 2002 ; Garc\u00eda - Ruiz , 2003 ) , sometimes using a one - dimensional simulation program developed by JAXA .We fine - tune the conditions using two steps of the counter - diffusion method .The first is the gel - tube method ( Tanaka et al . , 2004 b ) and the second is the JAXA Crystallization Box ( JCB ) method which is identical to the flight configuration .", "label": "", "metadata": {}}
{"text": "The counter - diffusion method differs from the vapor - diffusion method on such points as the optimum concentration of protein and precipitant , and the nucleation possibility , etc .When the possibility of nucleation is very low in the counter - diffusion method , we apply a micro - seeding technique .Only samples which produce crystal growth with the counter - diffusion method are considered ready for launch by the review board .For launch , all samples are loaded by JAXA in the laboratories in Japan for Japanese and Malaysian users and in Moscow for Russian users or at the launch site in Baikonur , Kazakhstan , depending on the profile of crystal growth .", "label": "", "metadata": {}}
{"text": "Samples which start nucleation earlier are loaded in Baikonur .The duration of crystallization in space ranges from six weeks to four months .The ground - control experiment is always performed using the same protein sample and the same crystallization device as the space experiment .After the retrieval of the crystals from space , they are quickly inspected by microscope in Japan before being handed to users .We rate the appearance of the crystals to present information to the users and for JAXA 's data accumulation .If a crystal obtains a high score and the user requires assistance , JAXA offers support for harvesting crystals from the capillary and the cryo - protection of the crystals .", "label": "", "metadata": {}}
{"text": "In order to obtain meaningful results , we believe it is crucial that researchers using space for crystallization experiments are taken care of from the beginning of their experiment to the end .This is because opportunities to grow crystals in space are both infrequent and different from ordinary crystallization in the laboratory .Only a few users have the experience and know - how to obtain the best results on their own .Crystallization device in the Japanese experiment module Kibo .From the beginning of JAXA - GCF , we adopted the Granada Crystallization Box ( GCB ) as a crystallization device using the counter - diffusion method ( Garc\u00eda - Ruiz & Moreno , 1994 ; Garc\u00eda - Ruiz et al . , 2002 ; Garc\u00eda - Ruiz , 2003 ) .", "label": "", "metadata": {}}
{"text": "The main features of the JCB are the separate crystallization cells and the volumetric efficiency .Capillaries containing protein solutions are plugged with agarose gel and inserted into tubes containing crystallization solutions .Using the JCB , we can apply up to 144 different crystallization conditions in a limited space ( about 1 l ; 100 mm \u00d7 150 mm \u00d7 65 mm ) .The assembly of the JCB has been described previously ( Takahashi et al . , 2010 ) .As shown in Figs . 1 and 3 , two JCBs are coupled in a tray , and four trays are stacked and fastened with Teflon tape ( JCB unit ) .", "label": "", "metadata": {}}
{"text": "Then three holders are loaded into a canister which can be connected to the PCRF on the JEM for temperature control ( 293 K ) .Figure 3 Assembly of the crystallization device for launch .( a )The JCB consists of six capillaries in a syringe case .Capillaries containing protein solutions are plugged with agarose gel and inserted into tubes , or cells , containing crystallization solutions .( b )To save space , two JCBs are coupled , i.e. the capillaries of two JCBs are positioned to fit between the slots of each other and they are put in a tray .", "label": "", "metadata": {}}
{"text": "( d )A metallic holder contains one JCB unit .The scale bars correspond to 10 mm .During transport to and from the ISS , the temperature control is completely passive .Sometimes the temperature inside the Soyuz rises above 303 K. Therefore , a phase transition material , heptadecane , in a number of plastic bags and a vacuum insulator are positioned to cover the canister .Since the melting point of heptadecane is 295 K , it can keep the protein samples at lower than 295 K until it melts completely .If we use enough of the material , the temperature stays stable .", "label": "", "metadata": {}}
{"text": "The usefulness of space experiments is shown in Table 2 at each step of the standard protocol in Fig . 2 .Therefore , we concluded that it is very important to improve the quality of the protein sample for successful space experiments .Table 2 Usefulness of space experiments at each step of the standard protocol .The usefulness of space experiments is calculated at each step of the standard protocol .A ' good result ' means that the quality of the crystals grown in space , indexed by maximum resolution or mosaicity , was higher than that of the best ground - grown crystal , and the X - ray diffraction data set advanced the research of the users .", "label": "", "metadata": {}}
{"text": "The crystallization cell is made of Techbarrier ( Mitsubishi Plastics , Tokyo , Japan ) so no water vapor or oxygen can permeate it .It can contain about 3.5 times as much reservoir solution as the JCB with the same volumetric efficiency , so the precipitant will not be diluted in the capillary and its concentration in the protein solution can be higher than that in the JCB .Moreover , the assembly of the JCB - SGT is much easier than the JCB , reducing the time for sample loading .We are now in the development phase of an upgraded version of crystallization cells for large crystals ( JCB - SLC ) .", "label": "", "metadata": {}}
{"text": "JAXA has developed technologies for the purpose of maximizing the usage of the microgravity environment .Our aim for the future is to make crystallization experiments in space a customary platform for researchers .In the 1990s , it was said that the contribution of space crystallization to structural biology was only limited .As of now , however , in JAXA PCG , in about 70 % of the cases , we have obtained crystals of improved quality in space when the crystallization conditions were properly optimized .We will distribute our methodology for space crystallization to users who want to obtain good - quality crystals .", "label": "", "metadata": {}}
{"text": "The most integral part of successful crystal growth in space is to make sure that high - quality crystals are able to grow under the same conditions on the ground beforehand .With these things in place , space - grown crystals can yield superior X - ray diffraction data which is very unlikely with crystals grown in a laboratory .As we obtain good results from space - grown crystals , space experiments to test results using different ligands may contribute to obtaining high - resolution data of proteins for drug design etc .There are still more details to be elucidated , but when our technique is more sophisticated and can be applied to a larger variety of protein samples , crystallization in microgravity will be a more useful methodology and will improve the efficiency of the structural analysis of proteins .", "label": "", "metadata": {}}
{"text": "We are thankful to Professor Atsushi Nakagawa of Osaka University , Professor Yoshiki Higuchi of University of Hyogo , and Professor Sam - Yong Park of Yokohama City University in the International Space Station Applied Research Partnership Program since 2004 .We thank Dr Yoshihiro Urade of Osaka Bioscience Institute for his long - term participation in crystallization experiments in microgravity .We thank the academic and research institutional users of JAXA PCG experiments for contributing protein samples to the microgravity experiments .References .Chernov , A. A. , Garc\u00eda - Ruiz , J. M. & Thomas , B. R. ( 2001 ) .", "label": "", "metadata": {}}
{"text": "Growth , 232 , 184 - 187 .Web of Science CrossRef CAS Garc\u00eda - Ruiz , J. M. ( 2003 ) .Methods Enzymol .Web of Science PubMed Garc\u00eda - Ruiz , J. M. , Gonzalez - Ramirez , L. A. , Gavira , J. A. & Ot\u00e1lora , F. ( 2002 ) .Acta Cryst .D 58 , 1638 - 1642 .Web of Science CrossRef IUCr Journals Garc\u00eda - Ruiz , J. M. & Moreno , A. ( 1994 ) .Acta Cryst .D 50 , 484 - 490 .Cryst .Growth Des .", "label": "", "metadata": {}}
{"text": "Defect Diffus .Forum , 323 - 325 , 565 - 569 .CrossRef CAS Littke , W. & John , C. ( 1986 ) .J. Cryst .Growth , 76 , 663 - 672 .CrossRef CAS Web of Science McPherson , A. ( 1999 ) .Crystallization of Biological Macromolecules , ch .10 , pp .435 - 472 .New York : Cold Spring Harbor Laboratory Press .Ot\u00e1lora , F. , Gavira , J. A. , Ng , J. D. & Garc\u00eda - Ruiz , J. M. ( 2009 ) .Prog .Biophys .", "label": "", "metadata": {}}
{"text": "Biol .Web of Science PubMed Ot\u00e1lora , F. , Novella , M. L. , Gavira , J. A. , Thomas , B. R. & Garc\u00eda - Ruiz , J. M. ( 2001 ) .Acta Cryst .D 57 , 412 - 417 .Microgravity Sci .Technol .Web of Science CrossRef CAS Snell , E. H. & Helliwell , J. R. ( 2005 ) .Rep. Prog .Phys .Acta Cryst .F 66 , 846 - 850 .Web of Science CrossRef CAS IUCr Journals Tanaka , H. , Inaka , K. , Furubayashi , N. , Yamanaka , M. , Takahashi , S. , Sano , S. , Sato , M. , Shirakawa , M. & Yoshimura , Y. ( 2012 ) .", "label": "", "metadata": {}}
{"text": "Forum 323 - 325 , 549 - 554 .CrossRef CAS Tanaka , H. , Inaka , K. , Sugiyama , S. , Takahashi , S. , Sano , S. , Sato , M. & Yoshitomi , S. ( 2004 a ) .Ann .NY Acad .Sci .Web of Science CrossRef PubMed CAS Tanaka , H. , Inaka , K. , Sugiyama , S. , Takahashi , S. , Sano , S. , Sato , M. & Yoshitomi , S. ( 2004 b ) .J. Synchrotron Rad .J. Synchrotron Rad .Microgravity Sci .Technol .", "label": "", "metadata": {}}
{"text": "J. Cryst .Growth , 211 , 149 - 156 .Web of Science CrossRef CAS Vergara , A. , Lorber , B. , Sauter , C. , Gieg\u00e9 , R. & Zagari , A. ( 2005 ) .Biophys .Chem .Web of Science CrossRef PubMed CAS Yamanaka , M. , Inaka , K. , Furubayashi , N. , Matsushima , M. , Takahashi , S. , Tanaka , H. , Sano , S. , Sato , M. , Kobayashi , T. & Tanaka , T. ( 2011 ) .J. Synchrotron Rad .Web of Science CrossRef CAS IUCr Journals .", "label": "", "metadata": {}}
{"text": "Figures .Abstract .Background .The population with multiple chronic conditions is growing .Prior studies indicate that patients with comorbidities are frequently excluded from trials but do not address whether information is available in trials to draw conclusions about treatment effects for these patients .Methods and Findings .We conducted a literature survey of trials from 11 Cochrane Reviews for four chronic diseases ( diabetes , heart failure , chronic obstructive pulmonary disease , and stroke ) .The Cochrane Reviews systematically identified and summarized trials on the effectiveness of diuretics , metformin , anticoagulants , longacting beta - agonists alone or in combination with inhaled corticosteroids , lipid lowering agents , exercise and diet .", "label": "", "metadata": {}}
{"text": "We assessed the exclusion and inclusion of people with comorbidities , the reporting of comorbidities , and whether comorbidities were considered as potential modifiers of treatment effects .Trials excluded patients with many common comorbidities .The proportion of exclusions for comorbidities ranged from 0 - 42 percent for heart failure , 0 - 55 percent for COPD , 0 - 44 percent for diabetes , and 0 - 39 percent for stroke .Seventy of the 161 trials ( 43.5 % ) described the prevalence of any comorbidity among participants with the index disease .The reporting of comorbidities in trials was very limited , in terms of reporting an operational definition and method of ascertainment for the presence of comorbidity and treatments for the comorbidity .", "label": "", "metadata": {}}
{"text": "Conclusions .Comorbidities receive little attention in chronic disease trials .Given the public health importance of people with multiple chronic conditions , trials should better report on comorbidities and assess the effect comorbidities have on treatment outcomes .Citation : Boyd CM , Vollenweider D , Puhan MA ( 2012 )Informing Evidence - Based Decision - Making for Patients with Comorbidity : Availability of Necessary Information in Clinical Trials for Chronic Diseases .PLoS ONE 7(8 ) : e41601 .doi:10.1371/journal.pone.0041601 .Editor : Isabelle Boutron , University Paris Descartes , France .Received : April 5 , 2012 ; Accepted : June 22 , 2012 ; Published : August 3 , 2012 .", "label": "", "metadata": {}}
{"text": "This is an open - access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited .The funders had no role in study design , data collection and analysis , decision to publish , or preparation of the manuscript .This does not alter the authors ' adherence to all the PLoS ONE policies on sharing data and materials .Introduction .Recent reports have posed concerns about the challenges of caring for a growing population with multiple chronic conditions [ 1 ] - [ 7 ] .", "label": "", "metadata": {}}
{"text": "One concern is an inadequate evidence base .The roots of this problem extend throughout the translational path , from the generation of the evidence to the synthesis of the evidence upon which clinical practice guidelines depend [ 1 ] .Comorbid patients are frequently excluded from the relevant clinical trials [ 10 ] - [ 12 ] .And even when such patients are not explicitly excluded , it is often difficult to know whether the overall effect estimate can be extrapolated to individuals with comorbidities , or whether the effect of a treatment is different in those with or without comorbidities .", "label": "", "metadata": {}}
{"text": "These uncertainties about treatment effects in comorbid patients translate into systematic reviews and guideline development , making it difficult to establish treatment recommendations for these patients [ 1 ] .We designed this project to address these methodological issues .Many trials focus on treatments for a single condition , and may exclude people with comorbidities , and the typical primary hypothesis does not include effect modification .With rare exceptions , systematic reviews and guidelines also emphasize the single - disease perspective as they inherit the limitations of the trials and studies they review .For systematic reviews , the scientific community has not identified the best methods of determining and describing applicability of evidence for comorbid patients [ 17 ] .", "label": "", "metadata": {}}
{"text": "It is also unknown how many existing studies contain the necessary information to address comorbid patients in systematic reviews , and therefore in for clinical decision - making .Diabetes , congestive heart failure , chronic obstructive pulmonary disease ( COPD ) , and stroke may serve as typical conditions where we commonly see these methodological issues .Both older and younger people with these conditions often suffer from comorbidities [ 18 ] - [ 20 ] .While the number varies depending on the demographics of the population and the number of comorbidities assessed , less than 20 % of people with any these conditions have the condition in isolation [ 18 ] - [ 20 ] .", "label": "", "metadata": {}}
{"text": "If reporting is insufficient , clinicians , guideline developers , and policy makers will not be able to make well - informed recommendations for clinical practice .Therefore , the aim of this study was to assess the inclusion of people with comorbidities and the reporting of comorbidities in trials of these four major chronic diseases , and whether comorbidities were considered as potential modifiers of treatment effects .Methods .Study Design and Selection .We conducted a survey of trials reporting on drug and non - drug interventions in patients with the four common chronic diseases : COPD , heart failure , stroke and type II diabetes mellitus .", "label": "", "metadata": {}}
{"text": "We chose diseases associated with high morbidity , mortality and significant health care expenditures [ 22 ] - [ 24 ] .We focused on widely prescribed drug and non - drug therapies , and we wanted to have a complete set of trials .The Cochrane reviews described the search strategy and eligibility criteria .We retrieved the main reports of included RCTs and retrieved additional papers that described the methods of these trials .We did not consider abstracts and unpublished data used in the Cochrane reviews because they could not provide the level of detail that we needed .", "label": "", "metadata": {}}
{"text": "The bibliography of excluded trials is available on request .Data Extraction .Before systematically extracting data from each trial , we developed a codebook that provided a detailed description of the information to be extracted and how to score it .We pilot tested the data extraction forms and the codebook on a random sample of 10 articles .One reviewer extracted all data and at least one other reviewer checked the data .They recorded and discussed all disagreements .If they were not able to resolve an issue , a third reviewer examined the article and all three reviewers discussed the issue until they resolved it .", "label": "", "metadata": {}}
{"text": "Reporting and Replicability of Inclusion and Exclusion Criteria .In order for us to better understand the population for whom researchers assessed treatment effects , the trial must clearly define inclusion and exclusion criteria .This is one criterion used for gauging how to generalize treatment effect estimates to a specific patient or group of patients [ 10 ] , [ 13 ] , [ 36 ] , [ 37 ] .We recorded whether or not each trial reported its inclusion and exclusion criteria .More specifically , they rated the difficulty of applying the inclusion and exclusion criteria , as stated in the trial reports , to specific patients .", "label": "", "metadata": {}}
{"text": "Specific Exclusion Criteria .We chose conditions which are believed to be prevalent or potentially represent important treatment effect modifiers for these conditions [ 19 ] , [ 37 ] , [ 38 ] .We also recorded whether there were specific age exclusions .Disagreements in the categorization of these exclusion criteria were resolved by discussion .If a \" severe \" version of one of these conditions was an exclusion criterion , we recorded it as an exclusion , even if a mild form of the condition was not an exclusion criterion for the trial .We also recorded if the trial had exclusion criteria other than these listed above or not .", "label": "", "metadata": {}}
{"text": "We were also interested in how often comorbidities were included as part of the description of the characteristics of the trial participants as selection procedures and trial participation also affect the characteristics of the trial participants .We also recorded whether the studies reported any treatments for the comorbidities for which prevalence was reported .Are Comorbidities Treatment Effect Modifiers ?( Subgroup Analyses ) .Recognizing that authors have limited power to pre - plan subgroup analyses , we assessed how often and the way the study performed subgroup analyses using recently described criteria [ 21 ] , [ 39 ] , [ 40 ] .", "label": "", "metadata": {}}
{"text": "For those trials that did report one or more subgroup effects , we recorded whether the subgroup was related to a comorbidity .For those trials that reported a subgroup based on a comorbidity , we recorded whether these trials used an interaction term to compare effects across subgroups by comorbidity status and whether the trials assessed if the interaction terms were statistically independent from other subgroup effects .Competing Risks and Heterogeneity of Treatment Effect Due to Different Baseline Risks .We recorded whether the trials considering competing risks in the design and analysis of trials .We also were interested in whether or not the trials reported on the heterogeneity of treatments effects due to different baseline risks .", "label": "", "metadata": {}}
{"text": "We used descriptive statistics to summarize our findings across the entire set of trials , and stratified by disease and type of treatment ( drug vs. non - drug ) .We conducted all analyses using STATA for Windows version 10.1 ( Stata Corp. , College Station , Texas , U.S. ) .Results .We included 161 trials .The replicability of inclusion and exclusion criteria was moderate in general .( See Table 1 ) Overall , for all four chronic diseases , the replicability of inclusion criteria was mean [ standard deviation ( SD ) ] : 6.0 ( 2.1 ) , range ( min - max ) : 1 - 9.5 .", "label": "", "metadata": {}}
{"text": "For all four chronic diseases , the replicability of exclusion criteria was slightly worse , with a mean ( SD ) of 5.3 ( 2.1 ) , range ( min - max ) : 1 - 9.5 .Again , the inter - rater agreement was good , with a concordance correlation coefficient rho of 0.81 ( 95 % CI 0.76 - 0.87 ) , and a mean difference ( SD ) between reviewers of 0.02 ( 1.38 ) .Replicability did not vary much across diseases .( Table 1 ) .The proportion of exclusions for comorbidities ranged from 0 to 42 percent for heart failure trials , 0 to 55 percent for COPD trials , 0 to 44 percent for diabetes trials , and 0 to 39 percent for stroke trials .", "label": "", "metadata": {}}
{"text": "For example , 42 percent of heart failure trials excluded people with coronary artery disease , 19 percent of heart failure trials excluded people with renal insufficiency .Similarly , 38 percent of diabetes trials excluded people with coronary artery disease and 44 % excluded people with renal insufficiency .Twenty - seven percent of COPD trials excluded people with coronary artery disease , and 35 percent excluded people with musculoskeletal diseases .Among stroke trials , 30 % excluded people with coronary artery disease and 24 % excluded people with heart failure .The prevalence of the specific exclusions is reported in the Figure .", "label": "", "metadata": {}}
{"text": "The median number ( interquartile range ) of comorbidities reported in those 70 trials was 3 ( 2 - 4 ) , with 237 total comorbidities reported in these 70 trials .The majority of the 70 trials did not report definitions for these 237 comorbidities ; only forty - five ( 19.0 % ) of the reported 237 comorbidities in the 70 trials had a definition of the comorbidity .These trials ascertained comorbidity from patient report for 19 ( 8.0 % ) comorbidities , from baseline examination for 73 ( 30.8 % ) , from medical records for seven ( 3.0 % ) and from other methods for five ( 2.1 % ) .", "label": "", "metadata": {}}
{"text": "The studies infrequently described whether or not a person received treatment for a comorbidity .The studies described treatments for 40 ( 16.9 % ) of the 237 comorbidities , whereas the studies did not describe treatments for 193 ( 81.3 % ) comorbidities and were unclear for 4 ( 0.2 % ) comorbidities .Importantly , none of them used interaction terms to formally test for effect modification .Only one trial ( 0.6 % ) considered heterogeneity of treatment effect due to different baseline risks .No trials considered the effects of competing risks [ 16 ] .", "label": "", "metadata": {}}
{"text": "Our analysis , based on studies of patients with any of four major diseases , found that evidence on the effect of treatments on comorbid patients is limited .The replicability of the inclusion and exclusion criteria is only moderate , thus making it hard to judge whether a specific patient or patient population would have been eligible to participate , and making it hard to replicate the clinical trial .Trials excluded patients with many common comorbidities .The reporting of comorbidities in trials of these four major chronic diseases was very limited , and it was even less common that the studies assessed whether comorbidities were potential modifiers of treatment effects .", "label": "", "metadata": {}}
{"text": "Published reports of trials frequently modify eligibility criteria when compared to the original trial protocols , and that many of these relate to comorbidity [ 45 ] .The replicability of inclusion and exclusion criteria was poor in many of these studies , and only moderate on average , making it difficult to judge whether a patient or a specific patient population would have been eligible for the trial .This also makes it more difficult to replicate the study and compare populations across studies .Comparing populations across studies is an essential step for systematic reviews that attempt to synthesize the evidence base for specific clinical questions .", "label": "", "metadata": {}}
{"text": "The existence of multiple common comorbidities was a reason for exclusion in studies examining each of the four chronic diseases .For example , while 55 percent of COPD patients in a population - based study , the National Health and Nutrition Examination Study ( NHANES ) have arthritis , 35 percent of the COPD trials excluded people with musculoskeletal diseases [ 38 ] .Sixteen percent of 45 - 64 year old diabetic patients , and thirty percent of 65 and older diabetic patients , have low glomerular filtration rate [ 37 ] .However , 44 percent of the diabetes trials excluded patients with renal insufficiency .", "label": "", "metadata": {}}
{"text": "The mismatch of eligibility criteria and the characteristics of a patient or patient population with the disease , affects our confidence in applying the results of the trial to these patients or patient populations .Also important is understanding what the patient characteristics were of people enrolled in a trial [ 13 ] .Inclusion and exclusion criteria capture who was eligible , but may not reflect who was actually recruited for the trial .For example , even if older adults are not excluded from a trial , if the mean age is 50 years , with a SD of 15 , these results may not apply to an 80-year - old man with multiple chronic conditions .", "label": "", "metadata": {}}
{"text": "Among those studies that reported prevalence of any comorbidities , the average number of comorbidities reported on was three .The trials also infrequently reported the definition of comorbidity and how the information needed for these definitions was obtained .Thus , determining the comorbidity burden on average of people in these trials was next to impossible .And even if the trials reported this information , we need additional information to determine whether the results of the trials really apply to people with a specific comorbidity ( or comorbidities ) or risk profile .Heterogeneity of treatment effects may arise from differences in baseline risk of the primary outcome , risk of harm , competing risks , or relative risk reduction [ 16 ] , [ 43 ] , [ 47 ] , [ 48 ] .", "label": "", "metadata": {}}
{"text": "While the trials occasionally examined subgroups based on comorbidity status , they were never examined according to established criteria [ 39 ] .The trials also rarely considered heterogeneity of baseline risk and competing risks .The result is that it is rare that we can draw conclusions about the presence , or absence , of different treatment effects in people with comorbidity .We could overcome some of the limitations of the current evidence base by improved reporting of the eligibility criteria of trials and the comorbidities of patients included in trials .Greater specificity to the descriptions of inclusion and exclusion criteria would help maximize replicability .", "label": "", "metadata": {}}
{"text": "And although it is often challenging to assess how treatment effects differ according the extent of comorbidity ( sample size requirements may exceed feasibility ) , trials need to address questions of effect modification for common and important comorbidities for which there are prior hypotheses about potential effect modification .One potential solution could be to use observational studies to investigate effect modification by comorbidity [ 49 ] .Although observational studies are more prone to confounding , the evidence base could still be improved overall .Defining multimorbidity clearly in such analyses of trials and observational studies will be essential [ 50 ] .", "label": "", "metadata": {}}
{"text": "One solution would be to develop explicit guidance on how to rate the quality of evidence that is used for comorbid patients , which could then inform the strength of recommendations .Limitations of our study included our focus on trials included in systematic reviews for four chronic diseases .Information about trials in additional chronic diseases may better guide treatment for people with comorbidity [ 51 ] , [ 52 ] .Nevertheless , we chose Cochrane systematic reviews as the basis of our included trials in order to address the important challenge of how evidence syntheses can better address the important challenge of developing evidence - based guidance for people with comorbidity .", "label": "", "metadata": {}}
{"text": "While the Cochrane reviews are recent , some of the included studies are significantly older , and there may be differences over time in the extent comorbidities are considered and there were no exclusions in the Cochrane reviews for quality of evidence or risk of bias .We did not assess for changes in reporting over time .However , recent work on exclusion and inclusion criteria suggests that there is not variation over the last 15 years among a more selected group of studies from high - impact journals [ 11 ] .Our approach of classifying the exclusions was based on categories of exclusion , and may have grouped exclusions with varied definitions .", "label": "", "metadata": {}}
{"text": "Often , these operational details of a definition are not reported by the trials , as shown in our results .Conclusion .Comorbidities receive little attention in chronic disease trials , which is illustrated by exclusion of patients with comorbidities , poor reporting on the prevalence of comorbidities and description of how comorbidities are ascertained , and few investigations into how comorbidities influence the effects of treatments .With the increasing prevalence and public health importance of comorbid patients , [ 53 ] clinical trials should not only focus on an index disease but should report on comorbidities , and better assess the effect comorbidities have on treatment outcomes .", "label": "", "metadata": {}}
{"text": "The Corresponding Author(CB ) has the right to grant on behalf of all authors and does grant on behalf of all authors , an exclusive license ( or non exclusive for government employees ) on a worldwide basis to PLOS One .Author Contributions .Conceived and designed the experiments : CMB DV MAP .Performed the experiments : CMB DV MAP .Analyzed the data : CMB DV MAP .Wrote the paper : CMB DV MAP .Had the idea for the study : CMB MAP .Designed the study : CMB MAP .Developed the data collection form and collected the data : CMB DV MAP .", "label": "", "metadata": {}}
{"text": "Drafted the report : CMB .Revised the report for final publication : CMB DV MAP .Guarantors of this study CMB MAP .All authors had full access to all of the data ( including statistical reports and tables ) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis .References .Boyd CM , Darer J , Boult C , Fried LP , Boult L , et al .( 2005 ) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases : implications for pay for performance JAMA .", "label": "", "metadata": {}}
{"text": "Lugtenberg M , Burgers JS , Clancy C , Westert GP , Schneider EC ( 2011 )Current guidelines have limited applicability to patients with comorbid conditions : a systematic analysis of evidence - based guidelines .PLoS One 6(10 ) : e25987 . doi : 10.1371/journal.pone.0025987 .Van Spall HG , Toren A , Kiss A , Fowler RA ( 2007 ) Eligibility criteria of randomized controlled trials published in high - impact general medical journals : a systematic sampling review .JAMA 297(11 ) : 1233 - 40 .doi : 10.1001/jama.297.11.1233 .Zulman DM , Sussman JB , Chen X , Cigolle CT , Blaum CS , et al .", "label": "", "metadata": {}}
{"text": "Examining the evidence : a systematic review of the inclusion and analysis of older adults in randomized controlled trials .J Gen Intern Med 26(7 ) : 783 - 90 .doi : 10.1007/s11606 - 010 - 1629-x .Varadhan R , Weiss CO , Segal JB , Wu AW , Scharfstein D , et al .( 2010 )Evaluating health outcomes in the presence of competing risks : a review of statistical methods and clinical applications .Med Care 48(6 Suppl ) .S96 - 105 .doi : 10.1097/mlr.0b013e3181d99107 .Owens DK , Lohr KN , Atkins D , Treadwell JR , Reston JT , et al .", "label": "", "metadata": {}}
{"text": "Grading the strength of a body of evidence when comparing medical interventions - Agency for Healthcare Research and Quality and the Effective Health Care Program .J Clin Epidemiol May 63(5 ) : 513 - 23 .doi : 10.1016/j.jclinepi.2009.03.009 .Boyd C , Leff B , Weiss C , Wolff J , Clark R , et al .( 2010 ) Full Report : Clarifying Multimorbidity to Improve Targeting and Delivery of Clinical Services for Medicaid 19 .Populations .Center for Health Care Strategies , Inc. .Boyd CM , Leff B , Wolff JL , Yu Q , Zhou J , et al .", "label": "", "metadata": {}}
{"text": "Informing clinical practice guideline development and implementation : prevalence of coexisting conditions among adults with coronary heart disease .J Am Geriatr Soc 59(5 ) : 797 - 805 .doi : 10.1111/j.1532 - 5415.2011.03391.x .Druss BG , Marcus SC , Olfson M , Tanielian T , Elinson L , et al .( 2001 )Comparing the national economic burden of five chronic conditions .Health Aff ( Millwood ) 20(6 ) : 233 - 41 .doi : 10.1377/hlthaff.20.6.233 .Saenz A , Fernandez - Esteban I , Mataix A , Ausejo M , Roque M , et al .", "label": "", "metadata": {}}
{"text": "Cochrane database of systematic reviews ( Online ) ( 3)(3 ) : CD002966 . doi : 10.1007/bf03084605 .Orozco LJ , Buchleitner AM , Gimenez - Perez G , Roque I Figuls M , Richter B , et al .( 2008 ) Exercise or exercise and diet for preventing type 2 diabetes mellitus .Cochrane database of systematic reviews ( Online ) ( 3)(3 ) : CD003054 .doi : 10.1002/14651858 .cd003054.pub3 .Nannini LJ , Cates CJ , Lasserson TJ , Poole P ( 2007 ) Combined corticosteroid and long - acting beta - agonist in one inhaler versus long - acting beta - agonists for chronic obstructive pulmonary disease .", "label": "", "metadata": {}}
{"text": "doi : 10.1002/14651858 . cd006829.pub2 .Manktelow BN , Potter JF ( 2009 ) Interventions in the management of serum lipids for preventing stroke recurrence .Cochrane database of systematic reviews ( Online ) ( 3)(3 ) : CD002091 .doi : 10.1002/14651858 . cd002091.pub2 .Lacasse Y , Goldstein R , Lasserson TJ , Martin S ( 2006 ) Pulmonary rehabilitation for chronic obstructive pulmonary disease .Cochrane database of systematic reviews ( Online ) ( 4)(4 ) :CD003793 .doi : 10.1002/14651858 . cd003793.pub2 .Davies EJ , Moxham T , Rees K , Singh S , Coats AJ , et al .", "label": "", "metadata": {}}
{"text": "Cochrane database of systematic reviews ( Online ) ( 4)(4 ) : CD003331 .doi : 10.1002/14651858 . cd003331.pub3 .Appleton S , Poole P , Smith B , Veale A , Lasserson TJ , et al .( 2006 )Long - acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease .Cochrane database of systematic reviews ( Online ) 3(Journal Article ) .CD001104 . doi : 10.1002/14651858 . cd001104.pub2 .Algra A , De Schryver EL , van Gijn J , Kappelle LJ , Koudstaal PJ ( 2006 )Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin .", "label": "", "metadata": {}}
{"text": "CD001342 .doi : 10.1002/14651858 . cd001342.pub2 .Schnell KM , Weiss CO , Lee T , Krishnan JA , Leff B , et al .( 2012 )The prevalence of clinically - relevant comorbid conditions in patients with chronic obstructive pulmonary disease : data from the National Health and Nutrition Examination Survey 1999 - 2008 .BMC Pulm Med 13 12(1 ) : 26 .doi : 10.1186/1471 - 2466 - 12 - 26 .Sun X , Briel M , Walter SD , Guyatt GH ( 2010 )Is a subgroup effect believable ?Updating criteria to evaluate the credibility of subgroup analyses .", "label": "", "metadata": {}}
{"text": "340(Journal Article ) .c117 .doi : 10.1136/bmj.c117 .Blumle A , Meerpohl JJ , Rucker G , Antes G , Schumacher M , et al .( 2011 )Reporting of eligibility criteria of randomised trials : cohort study comparing trial protocols with subsequent articles .BMJ 342 : d1828 .doi : 10.1136/bmj.d1828 .He J , Ogden LG , Bazzano LA , Vupputuri S , Loria C , et al .( 2001 )Risk factors for congestive heart failure in US men and women : NHANES I epidemiologic follow - up study .", "label": "", "metadata": {}}
{"text": "doi : 10.1001/archinte.161.7.996 .Greenfield S , Billimek J , Pellegrini F , Franciosi M , De Berardis G , et al .( 2009 ) Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes : a cohort study .Ann Intern Med 151(12 ) : 854 - 60 .doi : 10.7326/0003 - 4819 - 151 - 12 - 200912150 - 00005 .Harrison M , Reeves D , Harkness E , Valderals J , Kennedy A , et al .( 2012 )A secondary analysis of the moderating effects of depression and multimorbidity on the effectiveness of a chronic disease self - management programme .", "label": "", "metadata": {}}
{"text": "doi : 10.1016/j.pec.2011.06.007 .Ring A , Sestak I , Baum M , Howell A , Buzdar A , et al .( 2011 )Influence of comorbidities and age on risk of death without recurrence : a retrospective analysis of the Arimidex , Tamoxifen Alone or in Combination trial .J Clin Oncol 29(32 ) : 4266 - 72 .doi : 10.1200/jco.2011.35.5545 .Organisation of Economic Cooperation and Development .50th Anniversary Conference . html .Accessed 2012 Feb 9 .Additions to the Human Plasma Proteome via a Tandem MARS Depletion iTRAQ - Based Workflow .", "label": "", "metadata": {}}
{"text": "Academic Editor :Visith Thongboonkerd .Copyright \u00a9 2013 Zhiyun Cao et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .Abstract .Robust platforms for determining differentially expressed proteins in biomarker and discovery studies using human plasma are of great interest .While increased depth in proteome coverage is desirable , it is associated with costs of experimental time due to necessary sample fractionation .We evaluated a robust quantitative proteomics workflow for its ability ( 1 ) to provide increased depth in plasma proteome coverage and ( 2 ) to give statistical insight useful for establishing differentially expressed plasma proteins .", "label": "", "metadata": {}}
{"text": "Independent workflow experiments were performed in triplicate on four plasma samples tagged with iTRAQ 4-plex reagents .After stringent criteria were applied to database searched results , 689 proteins with at least two spectral counts ( SC ) were identified .Depth in proteome coverage was assessed by comparison to the 2010 Human Plasma Proteome Reference Database in which our studies reveal 399 additional proteins which have not been previously reported .Additionally , we report on the technical variation of this quantitative workflow which ranges from \u00b111 to 30 % .Introduction .Low - abundance proteins , which are of interest for biomarker applications , are often only accessible with involved proteomics workflows that utilize multiple sample fractionation steps .", "label": "", "metadata": {}}
{"text": "Enrichment strategies for low - abundance plasma proteins rely on immunodepletion of high - abundance proteins [ 2 - 5 ] , and , more recently , tandem depletion strategies have been employed [ 6 - 9 ] .A two - stage depletion setup that involves serial IgY and Supermix columns has also been effective in increasing the number of detectable low abundance proteins without affecting quantitative accuracy and precision using isobaric tags for relative and absolute quantification ( iTRAQ )[ 6 ] .Recently , an updated reference database of human plasma proteins was released from the Human Proteome Organization which includes 1929 nonredundant protein sequences [ 10 ] .", "label": "", "metadata": {}}
{"text": "Quantitative proteomics analyses of plasma are useful for identifying clinically relevant biomarkers [ 4 ] or in understanding disease mechanisms such as Alzheimer 's disease [ 11 ] .The inherent biological variability across human patients can require a large number of samples in order to determine differentially expressed proteins that are statistically relevant .Depending on factors such as instrumental platform and available instrument time , multiplexing strategies are attractive .The commercial iTRAQ reagent allows up to eight samples to be multiplexed and has been effective in identifying biomarkers or differentially expressed proteins in diseases [ 12 - 14 ] .", "label": "", "metadata": {}}
{"text": "Nonetheless , iTRAQ can provide reliable quantitative information depending on the statistical rigor required for denoting proteins as differentially expressed [ 6 , 16 - 19 ] .Several reports have stressed the importance of biological and technical replication in iTRAQ - based quantitative studies [ 13 , 16 , 19 , 20 ] .These reports , however , do not converge on the same finite set of criteria for determining statistically relevant differentially expressed proteins .For example , Song et al . suggest that at least 20 or 8 biological samples are required in order to use fold change cutoff values of 1.5 and 2.0 , respectively [ 19 ] .", "label": "", "metadata": {}}
{"text": "Herein , we evaluate a robust tandem depletion quantitative proteomics workflow for its ability to provide additional insight to the human plasma proteome and to provide suitable criteria for the statistically relevant determination of differentially expressed proteins in human plasma .Materials and Methods .Plasma Samples .Four plasma samples were obtained from patients enrolled in the Genetic and Inflammatory Markers of Sepsis ( GenIMS ) study [ 23 ] .These patients were initially diagnosed with community - acquired pneumonia upon admittance to the emergency department , and samples were collected ; however , further diagnoses revealed improper initial assessment .", "label": "", "metadata": {}}
{"text": "Approval for the participation of human subjects was obtained by the institutional review board of the University of Pittsburgh and other participating sites .Tandem MARS Immunodepletion ( TMD ) .The Hu 6 MARS column depletes serum albumin , IgG , \u03b1 1-antitrypsin , IgA , transferrin , and haptoglobin proteins .The second flow - through fractions ( hereafter referred to as TMD ) were concentrated , and protein concentrations were measured using the BCA protein assay .Protein Digestion and iTRAQ Labeling .In order to normalize experimental conditions , similar amounts of protein ( i.e. , 100 \u03bc g ) as determined from a BCA assay were employed .", "label": "", "metadata": {}}
{"text": "The alkylation reaction was quenched by adding 1 : 40 molar excess of cysteine , and the mixture was incubated at room temperature for 30 min .Each sample was labeled with an iTRAQ reagent following the manufacturer 's protocol ( Applied Biosystems ; Foster City , CA , USA ) with slight modifications .Briefly , each iTRAQ reagent was solubilized with 70 \u03bc L ethanol and transferred to peptide mixtures .After 1.5 h of incubation , the reaction was quenched by adding 50 \u03bc L of water .Labeled samples were mixed in 1 : 1 : 1 : 1 ratios for iTRAQ reagents that generate reporter ions m / z 114 : 115 : 116 : 117 , respectively .", "label": "", "metadata": {}}
{"text": "For strong - cation exchange ( SCX ) liquid chromatography the separation was carried out on a polysulfoethyl 100 mm \u00d7 2.1 mm , 5 \u03bc m , 200 \u00c5 column ( The Nest Group Inc. ; Southborough , MA , USA ) with buffers as follows .Mobile phase A was 5 mM monopotassium phosphate ( 25 % v / v acetonitrile , pH 3.0 ) , and mobile phase B was 5 mM phosphate and 350 mM potassium chloride ( 25 % v / v acetonitrile , pH 3.0 ) .Dried iTRAQ - labeled samples were resuspended in 300 \u03bc L of mobile phase A and injected onto the SCX column .", "label": "", "metadata": {}}
{"text": "Online desalting and reversed phase chromatography was performed with a Nano 2D - LC system equipped with an autosampler ( Eksigent ; Dublin , CA , USA ) .Mobile phase A and B for these analyses were 3 % ( v / v ) acetonitrile with 0.1 % formic acid and 100 % ( v / v ) acetonitrile with 0.1 % formic acid , respectively .SCX fractions were solubilized in 50 \u03bc L of H 2 O with 0.1 % formic acid and filtered with a 0.45 \u03bc m filter ( Thermo Fisher Scientific ; Waltham , MA , USA ) .", "label": "", "metadata": {}}
{"text": "After desalting , the sample was loaded into the analytical column ( 75 \u03bc m i.d.\u00d7 13.2 cm ) , which was packed in - house with C 18 100 \u00c5 stationary phase material ( Michrom Bioresource Inc. ) .The LC eluent was analyzed with positive - ion nanoflow electrospray using a LTQ - Orbitrap Velos mass spectrometer ( Thermo - Fisher Scientific , Waltham , MA , USA ) .Each fraction was subject to triplicate LC - MS / MS .Database Searching .RAW files were analyzed with Proteome Discoverer 1.2 software ( Thermo ) .", "label": "", "metadata": {}}
{"text": "Decoy database searching was employed to generate medium ( . ) confidence peptide lists .All peptides with medium and high confidence were pooled into a single data file and used for final protein identification and quantitation .Proteins with at least two spectral counts in a workflow replicate were included for identification .Only proteins with at least two spectral counts in a technical replicate were considered for quantitative and statistical analysis .One - way ANOVA analysis ( . ) was performed for proteins quantified in at least two workflow replicates utilizing Microsoft Excel .Protein Quantification and Statistical Analysis .", "label": "", "metadata": {}}
{"text": "The protein ratios were the median ratio of the corresponding peptide ratios .Coefficients of variation ( CV ) values were calculated for ratios of proteins quantified in at least two workflow replicates .The mean CV value across workflow replicates was calculated and used as the total biological variation , . ) was performed for proteins quantified in at least two workflow replicates utilizing Microsoft Excel .Results and Discussion .A robust quantitative shotgun proteomics workflow ( Figure 1(a ) ) was assessed for its ability to identify new human plasma proteins and to guide future experimental designs .", "label": "", "metadata": {}}
{"text": "200 analyses per column ) and the iTRAQ reagents ( 5 analyses per kit ) .Immunodepletion of samples is very reproducible for single - stage MARS depletion ( MD , Figure 1(b ) ) and TMD ( Figure 1(c ) ) .It is apparent from the chromatograms ( Figures 1(b ) and 1(c ) ) that high abundance proteins ( i.e. , . min ) are substantially depleted after the TMD step .It should be noted that albumin was still detectable after TMD ( Supplementary Table S2 ) ; however other abundant proteins ( i.e. , \u03b1 -1-antitrypsin , IgG , IgA , transferrin , and haptoglobin ) did not have any observed peptide hits .", "label": "", "metadata": {}}
{"text": "Figure 1 : ( a )The iTRAQ - based quantitative platform used for plasma proteome analyses in which the flow - through fractions from four crude plasma samples ( A - D ) are modified with iTRAQ 4-plex reagents , pooled into a single mixture , and separated with offline SCX - LC - MS / MS .Example chromatograms ( . ) from three independent injections of plasma sample C upon ( b ) MD and ( c ) TMD are shown .TMD samples were used for further iTRAQ tagging reactions and analyzed with SCX LC - MS / MS ( Figure 1(a ) ) .", "label": "", "metadata": {}}
{"text": "The proteins identified in this study were compared to the recently released 2011 HUPO plasma protein database to assess the depth of proteome coverage .Although the incorporation of a dual depletion step and SCX fractionation increases experimental sample preparation time , our results support the necessity of these ( or similar ) steps for identification of commonly detected and novel plasma proteins .Due to different experimental designs , LC - MS / MS data acquisition settings , and searching engines , the number of identified proteins may vary a lot across different labs .It is also possible that a portion of the identifications are a result of profiles specific to the patient samples employed .", "label": "", "metadata": {}}
{"text": "A total of 207 proteins were observed in all three of the workflow experiments , and more than half of the total proteins were observed in a single workflow replicate ( Figure 2(b ) ) .With more stringent criteria ( i.e. , not less than 2 unique peptides for protein identification ) , 229 proteins were identified across three workflow replicates , and 40 new proteins were identified in these studies in comparison to the HUPO database .Figure 2 : ( a ) Venn diagram for proteins identified in the human plasma proteome project ( HPPP ) and the TMD workflow presented herein .", "label": "", "metadata": {}}
{"text": "The datasets collected from this TMD strategy were used to examine the variation in the entire workflow .iTRAQ reporter ion ( i.e. , m / z 115 , 116 , and 117 ) ratios were calculated with respect to m / z 114 for each protein .Proteins quantified by at least 2 spectral counts were used in the assessment of variation .Of the 207 proteins identified in all three workflow replicates , 139 proteins ( with at least 2 spectral counts ) were quantified in the Proteome Discoverer Analysis .These proteins were used to initially assess the variance in reporter ion ratios across the workflow replicates ( of which each includes three technical replicates ) by employing well - established statistical approaches [ 25 , 28 - 31 ] .", "label": "", "metadata": {}}
{"text": "Thus within a single workflow experiment three technical replicates were measured .The workflow replicate assesses the variation beginning with the start of the plasma sample preparation .Figure 3(a ) plots the distribution of CV values for proteins as a function of reporter ion ratios ( e.g. , 115/114 , 116/114 , and 117/114 ) .The distribution of SD values for proteins as a function of log 2 transformed ratios are provided in Supplementary Figure 1 .Within a single workflow replicate , the average reporter ion ratio across technical replicates was calculated for individual proteins .The corresponding mean ( and median )", "label": "", "metadata": {}}
{"text": "0.21 when reporter ion 114 was used as the reference channel .Because the reporter ion channel used as the reference can have some effect on quantitation [ 19 ] , the mean ( and median )CV values were also calculated for different reference channels ( Supplementary Table S3 ) .This range of CV values that results from selection of different reference channels reflects the variation inherent in the four plasma samples as well as any variation that arises during LC - MS / MS analysis .( dashed circle ) are shown .CV values are given as fractional values .", "label": "", "metadata": {}}
{"text": "( b )Plot of the mean CV values for reporter ion ratios relative to reference channel 114 as a function of the number of spectral counts identified for each protein .Only proteins identified in all three workflow replicates are represented in this plot .( c ) Power analysis for iTRAQ - based quantitative platform whereby fold change values are plotted for a given number of biological replicates as a function of the number of technical replicates ( i.e. , . to 4 ) .The power and significance level values were set to 80 % and 0.05 , respectively .", "label": "", "metadata": {}}
{"text": "Higher variability in reporter ion ratios correlated with proteins that were identified with lower numbers of spectral counts ( Figure 3(b ) ) .In order to estimate the overall variance of this workflow , CV values were obtained for proteins quantified in at least two of the workflow replicates ( . )The mean CV was 0.21 , 0.15 , and 0.13 for ratios 115/114 , 116/114 , and 117/114 , respectively , and similar values were obtained for other reference channels ( Supplementary Table S3 ) .Herein , the technical variation was assessed by considering proteins observed in multiple LC - MS / MS analyses for individual workflow replicates .", "label": "", "metadata": {}}
{"text": "[ 31 ] was carried out .Power analysis was also performed in order to assess the fold - change criterion that should be applied based on a given number of biological replicates ( Figure 3(c ) ) .We note that our experimental approach ( i.e. , repeating the workflow using new aliquots of the same plasma samples ) does not represent a true biological replicate .However , this analysis still provides statistical insight to the power of biological replication in future experimental designs .The total biological variance ( . ) , power , and significance level applied were 0.16 , 0.10 , 80 % , and 0.05 , respectively .", "label": "", "metadata": {}}
{"text": "Technical replicates do not appear to have a significant effect on the fold - change criterion when multiple biological replicates will be used ( Figure 3(c ) ) .These data provide additional evidence to support the notion that biological replication ( i.e. , in these studies workflow replication ) is one of the most important factors that should be considered in the experimental design [ 16 , 21 , 25 ] .This paper has presented a robust quantitative plasma proteomics workflow that involves tandem MARS depletion , iTRAQ tagging , and SCX - LC - MS / MS analysis .", "label": "", "metadata": {}}
{"text": "The overall variation in the presented workflow ranges from \u00b111 to 30 % , and power analysis indicates that increasing biological replication would allow a lower fold - change cutoff to be applied to determine statistically relevant differentially expressed proteins .Future studies from our laboratory involve the application of this workflow to specific disease states whereby biological replicates are also being incorporated into the experimental design .Conflict of Interests .The authors have declared no conflict of interests .Acknowledgments .The authors acknowledge the University of Pittsburgh and the Society of Analytical Chemists in Pittsburgh for funds to support this work and the CRISMA laboratory for plasma samples .", "label": "", "metadata": {}}
{"text": "References .N. L. Anderson and N. G. Anderson , \" The human plasma proteome : history , character , and diagnostic prospects , \" Molecular & Cellular Proteomics , vol .1 , no .11 , pp .845 - 867 , 2002 .View at Google Scholar \u00b7 View at Scopus .C. Tu , P. A. Rudnick , M. Y. Martinez et al . , \" Depletion of abundant plasma proteins and limitations of plasma proteomics , \" Journal of Proteome Research , vol .9 , no .10 , pp .4982 - 4991 , 2010 .", "label": "", "metadata": {}}
{"text": "P. Juhasz , M. Lynch , M. Sethuraman et al . , \" Semi - targeted plasma proteomics discovery workflow utilizing two - stage protein depletion and off - line LC - MALDI MS / MS , \" Journal of Proteome Research , vol .10 , no . 1 , pp .34 - 45 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Mortezai , S. N. Harder , C. Schnabel et al . , \" Tandem affinity depletion : a combination of affinity fractionation and immunoaffinity depletion allows the detection of low - abundance components in the complex proteomes of body fluids , \" Journal of Proteome Research , vol .", "label": "", "metadata": {}}
{"text": "12 , pp .6126 - 6134 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W.-J. Qian , D. T. Kaleta , B. A. Ogata et al . , \" Enhanced detection of low abundant human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy , \" Molecular & Cellular Proteomics , vol .7 , no .10 , pp .1963 - 1973 , 2008 .View at Publisher \u00b7 View at Google Scholar .C. M. Shuford , A. M. Hawkridge , J. C. Burnett , and D. C. Muddiman , \" Utilizing spectral counting to quantitatively characterize tandem removal of abundant proteins ( TRAP ) in human plasma , \" Analytical Chemistry , vol .", "label": "", "metadata": {}}
{"text": "24 , pp .10179- 10185 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Farrah , E. W. Deutsch , G. S. Omenn et al . , \" A high - confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas , \" Molecular & Cellular Proteomics , vol .10 , Article ID M110.006353 , 2011 .View at Publisher \u00b7 View at Google Scholar .C. D. Aluise , R. A. Sowell , and D. A. Butterfield , \" Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction , diagnosis , and monitoring of therapeutic efficacy of Alzheimer 's disease , \" Biochimica et Biophysica Acta , vol .", "label": "", "metadata": {}}
{"text": "10 , pp .549 - 558 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Boja , T. Hiltke , R. Rivers et al . , \" Evolution of clinical proteomics and its role in medicine , \" Journal of Proteome Research , vol .10 , no . 1 , pp .66 - 84 , 2011 .View at Google Scholar . D. Han , S. Moon , H. Kim et al . , \" Detection of differential proteomes associated with the development of type 2 diabetes in the Zucker rat model using the iTRAQ technique , \" Journal of Proteome Research , vol .", "label": "", "metadata": {}}
{"text": "564 - 577 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. A. Karp , W. Huber , P. G. Sadowski , P. D. Charles , S. V. Hester , and K. S. Lilley , \" Addressing accuracy and precision issues in iTRAQ quantitation , \" Molecular and Cellular Proteomics , vol .9 , no . 9 , pp .1885 - 1897 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. G. Chee , K. C. Poh , K. P. Trong , and P. C. Wright , \" Technical , experimental , and biological variations in isobaric tags for relative and absolute quantitation ( iTRAQ ) , \" Journal of Proteome Research , vol .", "label": "", "metadata": {}}
{"text": "821 - 827 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. G. Hill , J. H. Schwacke , S. Comte - Walters et al . , \" A statistical model for iTRAQ data analysis , \" Journal of Proteome Research , vol .7 , no . 8 , pp .3091 - 3101 . A. L. Oberg , D. W. Mahoney , J. E. Eckel - Passow et al . , \" Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA , \" Journal of Proteome Research , vol .", "label": "", "metadata": {}}
{"text": "225 - 233 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. K. Chong , C. S. Gan , T. K. Pham , and P. C. Wright , \" Isobaric tags for relative and absolute quantitation ( iTRAQ ) reproducibility : implication of multiple injections , \" Journal of Proteome Research , vol .5 , no .5 , pp .1232 - 1240 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Zhou , K. L. Simpson , L. J. Lancashire et al . , \" Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery , \" Journal of Proteome Research , vol .", "label": "", "metadata": {}}
{"text": "4 , pp .2103 - 2113 , 2012 .View at Google Scholar .D. W. Mahoney , T. M. Therneau , C. J. Heppelmann et al . , \" Relative quantification : characterization of bias , variability and fold changes in mass spectrometry data from iTRAQ - labeled peptides , \" Journal of Proteome Research , vol .10 , no . 9 , pp .4325 - 4333 , 2011 .View at Google Scholar .J. A. Kellum , L. Kong , M. P. Fink et al . , \" Understanding the inflammatory cytokine response in pneumonia and sepsis : results of the genetic and inflammatory markers of sepsis ( GenIMS ) study , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}}
{"text": "15 , pp .1655 - 1663 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. K\u00f6cher , P. Pichler , M. Schutzbier et al . , \" High precision quantitative proteomics using iTRAQ on an LTQ Orbitrap : a new mass spectrometric method combining the benefits of all , \" Journal of Proteome Research , vol . 8 , no .10 , pp .4743 - 4752 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Ernoult , A. Bourreau , E. Gamelin , and C. Guette , \" A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation , \" Journal of Biomedicine & Biotechnology , vol .", "label": "", "metadata": {}}
{"text": "View at Google Scholar \u00b7 View at Scopus . H. Ye , L. Sun , X. Huang , P. Zhang , and X. Zhao , \" A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX - LC - MS / MS , \" Molecular and Cellular Biochemistry , vol .343 , no . 1 - 2 , pp .91 - 99 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. A. )Cairns , \" Statistical issues in quality control of proteomic analyses : good experimental design and planning , \" Proteomics , vol .", "label": "", "metadata": {}}
